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Abstract 
Pharmacists rarely receive the reason a medication was prescribed, often 
referred to as reason for use (RFU). Pharmacists can use this information to better 
counsel patients, support patients in taking medications safely, and improve patient 
understanding of why they are taking their medications. RFU can also be added to 
medication labels, giving patients another tool in helping them stay informed and safe 
when taking their medications.  
A total of 60 semi-structured interviews were conducted with pharmacists, 
prescribers and patients. Twenty interviews were conducted with each group, and were 
analyzed using thematic analysis to determine the impact of adding RFU on 
prescriptions and medication labels. Specifically, the impact to clinicians’ workflows, on 
interprofessional communication and patient safety and privacy were examined. 
Additionally, aspects relating to the logistics of including RFU on prescriptions and 
medications were considered.  
Most participants identified a number of benefits to including RFU on 
prescriptions and medication labels and ensuring that pharmacists are made aware of 
RFU. Participants from all groups noted that some patients may not want RFU listed on 
their medication bottles for privacy reasons, especially for medications to treat 
sensitive illnesses. These results indicate a need to ensure all members of the 
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healthcare team are informed about why a medication is being taken, and to support 
patients in taking their medications safely. 
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The desire to take medicine is perhaps the greatest feature which 
distinguishes man from animals. 
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Chapter 1: Introduction 
Medications are core to modern approaches to maintaining health, with 66% of 
Canadians aged 40-79 using at least one prescription medication in the last 30 days 
according to the Canadian Health Measures Survey (2016-2017).(1) Despite the number of 
prescriptions used to treat most medical conditions, research has demonstrated that only 
around 50% of patients with a chronic condition take their medication in accordance with 
their prescriber’s recommendations.(2,3) In Canada, it has been estimated that improper 
medication use accounts for up to 25% of hospital admissions.(4) 
In Ontario, prescribers are not required add the reason for use (RFU), or indication, 
for a medication on prescriptions.(5) As a result, to obtain an RFU for a prescription, the 
pharmacist must either use their professional judgement and guess, ask the patient, or 
contact the prescriber, all of which come with their own set of concerns.(6,7) Additionally, 
patients themselves may be unaware of their medications’ RFU, especially older patients 
who take multiple medications to manage chronic illnesses.(8)  Lack of awareness of RFU 
can lead to patients being confused about why they are using a given medication, and 
ultimately result in lower adherence.(9) 
In Ontario, when prescribers include the RFU on prescriptions, they typically do so 
by writing it in the prescription instructions, on a “case-by-case” basis.(5) Electronic 
medical records (EMRs), which are used for storing patient information and producing 
prescriptions to be sent to pharmacists, sometimes have functions that allow prescribers to 
include the RFU, but these can be cumbersome, are not often used, and do not 
automatically include this information in the prescription sent to the pharmacy.(10) 
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Additionally, there is debate between physicians in terms of how to present RFU.(11) Some 
physicians suggesting using scientific terminology, which would need to be interpreted by 
pharmacists during their consultation, and others recommending giving RFU in layperson 
terms, which may be easier for patients to understand without pharmacist 
intervention.(11) Other options have been suggested for communicating RFU as well. 
International Classification of Diseases (ICD) codes could be included on the prescriptions, 
ensuring both prescriber and pharmacist are able to precisely interpret the RFU. ICD codes 
take the form of three to seven-character codes. However, ICD codes may be prone to error 
when entered into a computer system to look up the code’s meaning.(12,13) 
After pharmacists receive RFU, it can also be included on medication prescription 
labels for use by patients.(11) This location is well suited because it is always attached to 
the original prescription bottle, and thus patients will have RFU information available to 
them, versus the information they remember, or that was provided on a separate 
paper.(14) Having access can improve patient understanding of their medication regime, 
thusly improving medication safety and adherence.(11)  
Including RFU on prescriptions can also benefit other prescribers. Patients are often 
asked to bring medications in their original bottles to specialist appointments or when 
checking into a hospital.(14) The inclusion of RFU on medication labels could additionally 
allow the non-prescribing physician to verify they have an understanding of why a patient 
is taking a specific medication, and in a hospital setting to understand what medications 
have been used thus-far to manage a particular illness.  
Adding RFU to prescriptions and medication labels could help support the safe and 
effective use of prescription medications but requires a number of stakeholders to agree to 
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share it.(9) The objective of this thesis was to investigate the perspectives of pharmacists, 
prescribers and patients with respect to the addition of RFU on prescriptions and 




Chapter 2: Overview and Literature Review 
This section provides an overview of key terms and concepts relating to 
medication use in the context of RFU, including health informatics, adherence, and 
medication indications, as well as a review of the current literature pertaining to RFU. 
2.1.1 Health Informatics 
Health informatics refers to the use of communication and information systems 
(ie, computers) to enhance individual and population health outcomes, specifically by 
targeting knowledge and information gaps within healthcare systems.(15,16) Health 
informatics includes the study of the health information technology used by clinicians 
to access patient and medical information.(17) Different clinicians use different tools to 
access this information, which are summarized in Table 1. 
Table 1: Types of information systems(17) 
 
Electronic medical 









∙ used by 
prescribers and 
clinical staff  
∙ used to access and 
add information 
about a patient 
seen in practice 
∙ located in a single 
practice, health 
team or hospital 
∙ used by 
pharmacists and 
pharmacy staff 
∙ used to manage 
medications and 
prescriptions 
∙ located in one or a 
network of 
pharmacies 
∙ used by various 
clinicians 
∙ contains similar 
info to an EMR, and 
can also include 
test results and lab 
values from 
external labs  
∙ contains 
information on 
∙ broad term to 
refer to EMRs, 
PMSs and EHRs 
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Electronic medical 









patients from a 
given region 
 
Current electronic health record (EHR) workflows for ordering medications 
include entering in the medication’s name, then if the prescriber chooses, adding the 
indication for the medication. Previous studies have shown that this process is often not 
followed and reason for use information is rarely added.(10,18) Li et al. previously 
found that just 15% of interviewed prescribers routinely include RFU on prescriptions, 
and Salazar et al. found that indications were included on just 7.4% of medication 
orders in their evaluation of inpatient records in Illinois.(10,19)  
Prescriptions are often faxed to pharmacies: this paper-based workflow presents 
challenges given that pharmacy management systems (PMSs) require the prescription 
to be re-entered manually into the computer.(18) Despite initiatives like tall man letters 
for look-alike medication names, or using scientifically incorrect but practically useful 
unit abbreviations (eg, mcg for microgram), entry errors still occur with EHRs.(6,20) 
Systems and initiatives that promote the routine inclusion of RFU would allow 
pharmacists to confirm the medication and dosage provided agrees with the indication 
listed.  
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2.1.2 Adherence, Concordance, and Compliance 
With patient-centered care becoming increasingly prominent in healthcare, the 
integration of the patient’s lived experience, wishes, and values are becoming central to 
the operation of the healthcare team. Concordance is the understanding that patients 
and clinicians arrive to with respect to medical choices, which involves the 
consideration of evidence and patient values.(21) This contrasts with compliance, 
which places the onus on patients for following prescriber instructions, and adherence, 
which describes patient’s ability and/or decision to follow medication treatment 
plans.(22) Current literature and clinical best practices suggest concordant 
relationships between healthcare providers and patients yield most optimal adherence 
to treatment plans.(22) While PMSs are not explicitly designed to support concordance, 
they can be used to determine patient adherence — specifically, if patients are taking 
their medications as instructed. PMSs can be used to calculate the elapsed time in 
between refills, versus the days’ supply provided.  
Quantifying patient-centered care is difficult and involves the patient’s 
subjective feelings and beliefs about how their healthcare team communicates with 
them, respects their wishes, and engages them in the decision-making process.(23) As 
such, efforts to improve patient adherence by using concordance strategies requires a 
commitment to patient-centered care and the development of strong, collaborative 
relationships between patients and their healthcare team.(23) 
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RFU is particularly relevant to patient adherence and concordance. Notably, 
pharmacists occupy an important role in medication counselling and review, and are a 
central figure who educates, reaffirms, and encourages concordant relationships 
between patients and prescribers.(24) Pharmacists, being the last healthcare provider 
that patients will interact with regarding their medication, can have a significant impact 
on patient attitude towards medication use.(25) Affirming prescriber decisions, 
including RFU information, is key to assuring patients who may be questioning whether 
to take their medications.(25)   
2.1.3 Medication Indications 
Indications are the basis on which an intervention or procedure is used, and  
lead to the determination of goals which overarchingly include the prevention, cure and 
care of illness and injury.(26,27) Separately, diagnoses are particular medical 
conditions, comprised of a collection of signs and symptoms.(28) Diagnoses and 
indications are separate but related pieces of information, which are coded and stored 
separately within health management systems (HMSs) often using the ICD-10 and 
Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT), 
respectively.(13,29,30)  
Indications provide a starting place to determine what information to include as 
a medication’s RFU, as the precise requirements for what constitutes an indication, and 
by extension RFU, are ill-defined.(9) Kron et al. presented the use of antihypertensives 
 
  8 
as a case of how determining a precise indication for a medication can be difficult: 
“preventing stroke,” “high blood pressure” and “hypertension” are all valid indications 
for antihypertensive medication.(9) Different constructs can be included under 
indications, including clinical trial indications, regulatory-agency approved indication, 
and computerized provider order entry (CPOE) indication. A precise definition for what 
should be included as RFU for a medication needs to be determined and implemented in 
an easy-to-use manner within EMRs.  
2.2 Key stakeholders in RFU information Flow 
Prescribers, pharmacists and patients all have an interest in ensuring that 
medication RFU is communicated clearly and effectively, to support adherence to 
medication therapy, accurate counselling and safe medication use. The current routes of 
communication about RFU, as well as areas where written RFU (wRFU) could be 
provided are detailed in Figure 1. Previous work regarding the sharing of RFU between 
these groups are described below.  
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Figure 1, Current RFU information flow. Speech bubbles denote verbal 
communication, either in person or on the phone. Prescribers (left) verbally 
explain RFU to patients (middle), who are expected to relay this information 
to pharmacists (right). As denoted by wRFU ,  prescriptions and medication 
labels represent opportunities to include RFU in a written format to improve 
communication about medications.  Image credits: doctor, prescription, pill 
bottle and speech bubble made by Freepik; pharmacist and person made by 
itim2101, all from www.flaticon.com. 
 
2.2.1 Pharmacists 
Pharmacists hold an important role in helping patients manage prescribed and 
over-the-counter medications, as well as treatment plans. Pharmacists represent the 
final opportunity to identify if a medication is appropriate, effective, safe, and if the 
patient is willing and able to take it. Further, pharmacists are responsible for 
communicating important information on prescribed medication before the patient 
takes the medication. Thus, from patient safety and medication adherence perspectives, 
pharmacists have a responsibility to assess why a medication is being used as part of 
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the dispensing process.(31) Providing pharmacists with access to RFU allows them to 
identify prescribing errors, reduce call-backs to prescribers, and improve their 
counselling to patients.(31–33) 
Pharmacist counselling has been shown to improve patient adherence to 
prescribed treatment regimens, however not having access to RFU has been shown to 
negatively impact pharmacists’ ability to provide counselling and education to 
patients.(9,34,35) Adding RFU to prescriptions would allow pharmacists to have a 
better understanding of their patients medications, provide more targeted counselling, 
and ultimately promote safe medication use. 
Pharmacists would also benefit from having access to RFU when providing 
medication reconciliation services, which can take place in hospitals or in the 
community. Hospital medication reconciliation services have been shown to reduce 
medication discrepancies, reduce the number of adverse drug events and save 
healthcare systems money at the time of discharge.(36–38) Community medication 
reconciliation services ensure complete medication lists, lead to a reduction in 
healthcare costs, and improvements on outcome measures for a number of chronic 
illnesses.(34,39) 
Finally, associating a prescription with an RFU directly supports deprescribing 
initiatives, as HMSs can be set to list medications according to why they were 
prescribed, and would thus allow pharmacists to review medications according to 
indication, as opposed to traditional chronological views.(9) This functionality, along 
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with the certainty in knowing why a particular medication was prescribed can allow 
pharmacists to feel confident in knowing that a particular medication is amenable to 
deprescription.   
2.2.2 Prescribers 
Prescribers are the gatekeepers of prescription medication use in the Canadian 
healthcare system, and can include a number of professions, including physicians and 
surgeons, dentists, optometrists, nurse practitioners, physician assistants, and in some 
jurisdictions, pharmacists.(40) To support patients in taking their medications safely 
and effectively, it makes good sense for prescribers to include RFU on prescriptions to 
facilitate patient understanding of their medications, counselling by pharmacists and 
ultimately adherence to prescribed medication regimes.(34) 
Despite these advantages, it has been shown that indications are included on 
prescriptions between 7% and 15% of the time.(10,19) In previous work by Mercer et 
al., physicians noted that they did not have access to adherence information from 
pharmacists, who do not routinely communicate this information to physicians.(14) 
Using EHRs to share information like RFU and adherence information, generated by 
prescribers and pharmacists, respectively, would facilitate the bidirectional flow of 
clinically relevant information to these parties.   
In Canadian provinces where provincial EHRs contain adherence and lab-value 
information, these data are not incorporated directly into pharmacist PMSs and 
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physician EMRs, which reinforces disconnected clinical practices. Facilitating RFU and 
adherence information is shared between prescribers and pharmacists would provide a 
benefit to both parties, and may serve to promote RFU addition by prescribers, despite 
prescriber concerns about increases in documentation.(41,42)  
2.2.3 Pharmacist-Prescriber Relationships and Communication 
Including an indication on prescriptions has the potential to improve the 
relationship between pharmacists and physicians. These clinicians are often not co-
located, communicate via dated technology (ie, fax, landline) and can experience 
professional role conflict, which can all lead to RFU not being shared.(43) Mercer et al. 
used semi-structured interviews to explore how physicians and pharmacists 
communicate patient-focused information, and the role that EHRs can play in 
supporting inter-professional decision-making processes.(6) Fax machines were found 
to be the most common method of communication between pharmacists and 
physicians, being well-trusted and creating a written record of their interactions.(43) 
However, the lack of integration between fax machines and EHRs was found to reduce 
the efficiency of this communication method, as information needs to be manually 
entered into HMSs. Difficulty in connecting with other healthcare practitioners (HCPs) 
was frequently mentioned, and both pharmacists and physicians expressed frustration 
when waiting for other HCPs to respond to messages.  
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Pharmacists also noted how their relationships with physicians could be 
strained due to a perceived power imbalance in the physician’s favour.(6) This became 
especially evident in provinces where pharmacists’ scope of practice has increased to 
include prescribing, which could cause “role friction” with some physicians.(6) Taken 
together, both groups need to develop strategies to facilitate interprofessional 
collaboration that go beyond information sharing, and extend to professional 
acceptance, clear, bidirectional communication with physicians and information 
systems which actively support both. 
The importance of clarifying roles, delineating role boundaries, and the 
influential role of personal relationships between clinicians to facilitate meaningful 
interactions was stressed as an opportunity to improve the relationships between 
physicians and pharmacists.(6) Additionally, the value of developing a mutual 
understanding of where each clinician expertise lays, and the development of systems 
that support active collaboration to create and reinforce interprofessional partnerships 
was highlighted.  
2.2.4 Patients 
While prescribers and pharmacists have important roles in facilitating safe 
medication use, patients themselves ultimately choose to take their medications. 
Certain demographic factors have been found to influence patients’ decisions to take 
their medications including: having a mental health illness, patients’ understanding of 
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their medications, age, education, and a being person of colour.(42,44–46) In particular, 
Garada et al. conducted semi-structured interviews with Australian patients, 
prescribers and pharmacists, and determined that having RFU on medication labels 
would make patients “more inclined to” take their medications.(42) Patients in the 
study expressed concern about adding RFU to medication labels to treat sexually 
transmitted infections (STIs) and psychiatric illnesses, due to the potential privacy risks 
of having RFU displayed publically.(42,47) 
Adding RFU onto prescriptions and mediation labels would directly support the 
safe use of medications by patients. Previous research has shown that 13% of patients 
did not know the indication of at least one of their medications in a primary care 
setting, and 96% of patients entirely omitted at least one hospital-prescribed 
medication when asked to provide their medication list.(48,49) As medicine moves 
increasingly towards patient-centered care, involving patients as partners in care, 
including through the safe use of medications, is important to ultimately support 
medication safety.(48) Additionally, as low health literacy has been observed to relate 
to decreased adherence, the addition of RFU to medication labels may lead to increased 
adherence.(50) 
One research study by Mercer et al. investigated how electronic access to health 
information via an EHR can be used to facilitate patient decision making.(14) Using 
semi-structured interviews, patients 18 years or older with at least one chronic illness 
from Alberta, Ontario, Quebec and Nova Scotia were recruited and asked about their 
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understanding and perception of EHRs. Patient use of EHRs to access health 
information was found to be non-existent, even in provinces where provincial EHRs 
with patient-facing interfaces exist. To that end, the patients were concerned about 
using EHRs to access their health information and make decisions.  
To support their care, patients expressed a desire for EHRs to communicate 
information between pharmacists and physicians, instead of the onus for information 
transmission being on them.(14) Patients discussed that EHRs could help them make 
decisions about their health in the future, as well as understand the rationale behind 
decisions made by their physicians. These results shed light on how EHRs can better 
serve the needs of patients.  
 
2.3 Initiatives and research promoting the addition of RFU to prescriptions and medication 
labels 
 
The existing body of research demonstrates the benefits, disadvantages, 
perspectives and impact of adding RFU to prescriptions and medication labels from the 
perspective of pharmacists, prescribers and patients. In addition, there is evidence that 
supports novel methods of ensuring that RFU is added and communicated clearly to all 
stakeholders and ultimately improves safe medication use.(18,31) Finally, policy and 
position papers detailing the value of adding RFU from a number of health 
organizations exist and are described below.(51,52) 
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2.3.1 Technological changes to promote RFU communication 
Ensuring that RFU information gets added and communicated to pharmacists 
and patients can be supported by improving the health information systems involved in 
the storage and transmission of RFU. Some changes proposed to EMRs and PMSs are 
detailed below.  
2.3.1.1 Indications-based prescribing  
Schiff pioneered the idea of “indications-based prescribing,” where prescribers 
enter an indication, then select a recommended medication, in a process detailed in 
Figure 2.(18) The goal of this work was to design a system to promote the routine 
addition of RFU on prescriptions, thereby enhancing medication safety.(9) By requiring 
that medications are selected only after an indication is included, indications-based 
prescribing ensures that prescriptions always include RFU.(18)   
 
Figure 2, Different prescribing paradigms. a) current prescribing paradigm; 
b) indications-based prescribing (bottom). 
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Schiff et al. developed a prototype CPOE incorporating indications-based 
prescribing, which was tested by 32 prescribers.(53) Their prototype, shown in Figure 
3, was shown to result in significantly shorter time and fewer mouse clicks to generate 
a prescription as well as requiring fewer references to external reference sources 
across a range of conditions versus participants’ preferred existing CPOE. In addition, it 
was also rated as easier to use versus existing CPOEs.(53) While not currently in 
routine use in any commercially-available CPOEs, the success of this trial of indications-
based prescribing lends to the value of incorporating indications-based prescribing. 
 
Figure 3, Schiff’s indications -based prescribing. a) prescribers enter an 
indication; b) a list of suggested treatments is presented, factoring in patient 
characteristics (eg, allergies); c) a drug order is generated automatically, 
including appropriate dosage, directions and indication . Provided under a 
CC-BY Licence, © 2019 Garabedian PM et al . JAMA Network Open. 
2.3.1.2 Changes to PMS Software 
Kerestecioglu et al. investigated the role of PMSs in the interactions between 
physicians and pharmacists as an area to improve communication between these 
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parties.(54) Field studies, interviews and talk-aloud explanations of HMS use by 
pharmacists and physicians were examined, and reasons for miscommunication 
between pharmacists and physicians and usability issues within the clinical software 
were identified. 
Reasons for miscommunication centered around difficulty in reaching the other 
provider, a sentiment expressed by both physicians and pharmacists. Additionally, the 
information disparity between pharmacists and physicians, with the former having 
access to markedly less information in Ontario due to a lack of EHR access, posed a 
barrier to effectively managing medications and making informed clinical decisions. 
Similar to work done by Mercer et al., the primary methods of communication 
frequently employed by these clinicians pose an additional barrier to developing 
collaborate relationships. Pharmacists and physicians often fax each other to transmit 
patient information and to ask questions — a method which does not allow for 
instantaneous feedback, or confirmation of message receipt.  Using fax as a 
communication method has been noted for its relative inefficiency.(54,55) Pharmacists 
and physicians both expressed a desire to communicate electronically directly through 
their HMSs, which would be more efficient, and instantaneous. 
Additionally, pharmacist-led medication reconciliation of over-the-counter and 
prescription medications were identified as a potential source of friction.(54) For 
example, should an issue be identified where the physician needs to be contacted for 
additional information, the medication review process cannot continue until the 
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physician responds, which could take as long as 15 days.(54) This, combined with an 
unknown response time, means that the entire medication reconciliation process can be 
unpredictable and lengthy for both patients and pharmacists.  
To address these concerns, Kerestecioglu designed a prototype feature to be 
added to PMSs called a Communications Summary.(54) The Communications Summary 
includes prescriber information (eg, name, specialty, licence number), a “call box” 
containing information on the pharmacist’s pending and completed medications that 
need attention from that physician, a panel indicating predicted response times and 
most likely days to receive a follow-up call, and finally an inbox containing information 
on the communication history with the physician. This tool was found to be effective in 
helping predict and understand prescriber response times and was found to aid 
productivity.   
2.3.2 Medication label redesigns to support RFU addition 
Hussein et al. investigated the implications of adding RFU onto prescription 
labels from the perspective of patients.(11) Three major reasons for communicating 
RFU more clearly in Ontario’s healthcare system were identified: to determine RFU for a 
medication prescribed off-label, to reduce errors so that a medication can be identified 
both by name and indication, and to increase patients’ knowledge about their 
medications.(11)  
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Hussein’s work identified the best practices in medication label design. The 
importance of plain language, uniform text orientation, contrast between text and the 
label’s background and a clear, legible, minimum 12-point, font were explicitly noted as 
contributing factors to the clarity of medication labelling.(11) Semi-structured 
interviews with patients revealed that the majority of patients rated the importance of 
knowing RFU as “very important,” and patients recommended RFU be written in lay 
language, using between one to three words. 
2.3.3 Policy and position papers surrounding RFU and medication safety 
 A number of organizations have advocated for the inclusion of RFU on 
prescriptions and medication labels.(9) These include the National Coordinating 
Council for Medication Error Reporting and Prevention, calling for a “brief notation of 
purpose” on prescriptions, (56) The U.S. Pharmacopeia recommending that if RFU is 
included on a prescription, that it “should be included on the prescription container 
label,”(51) and the National Association of Boards of Pharmacy “support[ing] legislative 
and regulatory efforts in the states to require prescribers to include the indication for 
the medication on all prescriptions and medication orders.”(52) Adding RFU on 
prescriptions and medication labels is complimentary to other medication safety 
initiatives as well, including the including Canadian Patient Safety Institute’s 
#ConquerSilence and Five Questions to Ask about your Medications campaigns. These and 
other organizations add to the pressure to communicate RFU more clearly.(57–59) 
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2.3.4 Canadian initiatives to support interprofessional communication  
 Despite the above initiatives, there has still been little advancement in the area 
of the routine addition of RFU to prescriptions and medication labels in all jurisdictions 
in Canada and the United States. Notably, in Quebec, the Medical Office of the XXI 
Century (MOXXI) EHR requires the addition of RFU, Figure 4.(60,61) Other Canadian 
initiatives are detailed below. 
 
Figure 4, Adding an indication using MOXXI. Image reprinted with the 
written permission of the McGill University Clinical and Health Informatics 
Research Group.  
2.3.4.1 Alberta Netcare  
Alberta rolled out a province-wide online EHR in 2008 called Netcare, containing 
protected health information (PHI) of Albertans, including medication records, lab 
results, hospital discharge reports and transcribed reports.(62) Netcare includes a 
messaging feature where clinicians can securely message other clinicians, based on the 
EHR software Epic.(63) Netcare is beneficial for pharmacists, allowing them access to 
the above data, alerts to medication conflicts, and ePrescriptions, which allows for 
faster prescription transfer to pharmacists, and eliminates information re-entry.  
Much of the PHI is accessible by patients themselves through Netcare’s Personal 
Health Portal. Additionally, patients are able to add in information about their health, 
such as glucometer or pedometer data, allowing them to contribute to their PHI, as well 
as giving them increased ownership of their health information.(64) Future revisions 
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will increase information parity with clinicians, providing lab values, discharge reports 
and records of physician visits to the patients themselves.(65) This information is 
provided to patients via login with provincial identification, which also serves as 
authentication for other online provincial services. By allowing patients access to their 
PHI, they can be able to better engage in the medical decision-making process and make 
more informed decisions.(66) 
2.3.4.2 Canada Health Infoway 
Alberta is actively participating in a trial of PrescribeIT®, a component of Canada 
Health Infoway.(67) Canada Health Infoway is a non-profit organization funded by the 
Government of Canada to facilitate the development, adoption and use of digital health 
solutions across Canada.(68) PrescribeIT® is a pan-Canada ePrescribing service, 
allowing prescriptions to be sent between prescribers and pharmacists throughout 
Canada. The service is proposed to either integrate with existing EMRs, or be accessed 
through a dedicated application.(69) By 2020, PrescribeIT® expects to be operational in 
Alberta, Ontario and New Brunswick.(70)  
PrescribeIT® will benefit pharmacists in similar ways to Alberta Netcare, 
including clinician messaging, eRenewals, and the possibility to eliminate manual entry 
of prescription details, reducing error.(71) In parallel with PrescribeIT®, Canada Health 
Infoway is developing ACCESS Digital Health, a pan-Canada EHR, with capabilities 
similar to Netcare, including clinician and patient access to information.(70) 
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2.4 Summary 
There are many potential benefits to pharmacists, physician and patients if RFU 
is added to prescriptions. By making this information readily available, there will be 
fewer clarifications between pharmacists and prescribers, allowing for conversations to 
be more collaborative rather than focused on information gathering. By increasing 
pharmacists’ ability to provide effective counseling, they will be better able to help 
patients improve their medication awareness, understanding, and ultimately adherence 
to prescribed treatment regimens. Technological and human-factors aspects present 
barriers to the routine addition of RFU to prescriptions and medication labels. 
Technology can make the addition of RFU more convenient, but clinicians still must 
make the active choice to include it. However, EHRs do have the potential to facilitate 
the inclusion of RFU on prescriptions by changing prescriber workflow (eg, Schiff’s 
indications-based prescribing, making it mandatory in a particular jurisdiction). Doing 
so may promote the routine inclusion of RFU on prescriptions. 
Building on existing research conducted with pharmacists, physician and 
patients about improving the communication of RFU, this work identifies additional 
barriers and facilitators to the inclusion of reason for use, ultimately supporting 
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Chapter 3: Pharmacists’ perspectives on the value of reason for use 
information 
This work is in press at the Canadian Pharmacists Journal. 
3.1 Introduction 
The use of medications is central to the way many illnesses are treated, however 
have the potential to cause substantial harm if used incorrectly. The global cost of 
medication errors was estimated to be US $42 billion in 2017.(72) Pharmacists have 
important roles in helping patients manage their prescription medications, and 
represent the final opportunity to identify if a medication is indicated, effective, safe, 
and if the patient is willing and able to take it. Further, pharmacists are responsible for 
providing any final information on the prescribed medication before the patient takes 
the medication. Thus, from patient safety and medication adherence perspectives, 
pharmacists have a responsibility to assess why a medication is being used as part of 
the dispensing process. In Ontario, prescribers are not required to provide pharmacists 
with the reason for use (RFU), or indication, for a medication.(5) 
 Current medication CPOE systems introduce a substantially greater workload 
when entering a medication’s indication. However, this can be easily overcome through 
a modified design and is the subject of other research.(18) This has led to a low number 
of prescribers adding RFU to prescriptions. The addition of RFU to prescriptions by 
prescribers would encourage patients and other clinicians to participate in medication-
related decision making, and facilitate stronger collaboration and communication 
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across the care team.(73) The addition of RFU on prescription labels has also been 
noted for its ability to improve patient safety and adherence, by ensuring patients are 
aware of which medications treat which illnesses.(7,74,75) RFU’s potential to improve 
pharmacist workflow was identified in multiple studies, and its current absence from 
prescriptions was noted as a barrier to efficient patient counselling.(33,76,77) Putting 
RFU on prescriptions cannot substitute for effective communication skills between 
pharmacists, physicians and patients, however, as this information can lack nuance and 
context.(7) 
Adding RFU to prescriptions and medication labels presents clear benefits to all 
healthcare providers and patients, but is still not part of routine clinical practice.(53) 
This paper explores the potential impact that adding RFU to prescriptions could have 
on pharmacy practice. The value of this research design is hearing directly from 
pharmacists about how having access to RFU would affect their clinical workflow and 
the counselling they provide patients. The objective of this paper was to understand 
how the workflow of pharmacists would be affected by receiving RFU from prescribers, 
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3.2 Methods 
We used a qualitative approach to ask pharmacists directly how their practice 
and clinical workflow would be impacted by receiving RFU from prescribers, and how 
the RFU information should be formatted to ensure its clinical utility.  
Semi-structured interviews were conducted with 20 pharmacists in 
Southwestern Ontario between March and July 2018. Interviews were done as a 
component of a broader study evaluating the perceptions of physicians, pharmacists 
and patients on how RFU would impact communication. Semi-structured interviews 
were used, as this allowed the interviewer flexibility to follow-up on key concepts 
mentioned by participants.(78) Ethics approval was received by a University of 
Waterloo ethics committee (ORE# 31591).  
 A random list of pharmacists who were in active practice was generated using 
the publicly available database from the Ontario College of Pharmacists website. 
Pharmacists were faxed a short survey that asked questions about RFU, and asking if 
they would answer questions about RFU in an in-person interview (Appendix A). Of the 
29 pharmacists faxed, 9 responded to the request agreeing to be interviewed. 
Additional pharmacists to interview were identified via snowball sampling, by asking 
participating pharmacists if they could refer any colleagues for interviewing. 
Demographic information can be found in Table 2. Pharmacists were interviewed at a 
time and location of their choosing, often their pharmacy. 
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Table 2, Demographic profile of pharmacist participants 
 
 ID Years in Practice  Current Practice 
Pharmacist 01 9 Independent 
Pharmacist 02 8 Independent 
Pharmacist 03 6 Chain store 
Pharmacist 04 unknown Chain store 
Pharmacist 05 25 Independent 
Pharmacist 06 5 Independent 
Pharmacist 07 3 Chain store 
Pharmacist 08 1 Chain store 
Pharmacist 09 1 Chain store 
Pharmacist 10 13 Independent 
Pharmacist 11 11 Independent 
Pharmacist 12 18 Independent 
Pharmacist 13 12 Chain store 
Pharmacist 14 13 Hospital 
Pharmacist 15 1 Chain store 
Pharmacist 16 25 Chain store 
Pharmacist 17 1 Chain store 
Pharmacist 18 1 Independent 
Pharmacist 19 15 Chain store 
Pharmacist 20 15 Independent 
3.2.1 Data collection 
Interviews were jointly conducted by pharmacy and systems design engineering 
researchers using a semi-structured interview guide (Appendix B). All interviews were 
recorded and transcribed. In the interviews, the pharmacists were asked a series of 
questions related to the following four areas: how they were using RFU now in practice; 
how they currently determine RFU; the impact that the inclusion of RFU on 
prescriptions would have on their practice; and their willingness to include RFU on 
prescription labels. The questions were generated by the research team after informal 
discussion and were finalized based on feedback from CB and KG, as well as an external 
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researcher. The interviewers probed when the answer to a question was not clear 
based on the participant’s response.  
3.2.2 Data analysis 
Transcripts were stored and analyzed using NVivo12 for Mac.(79) The 
engineering team separately analyzed the data, considering the data from pharmacists, 
physicians and patients, and presenting a model of the pharmacists’ decision making, as 
opposed to a more in-depth analysis of a single group’s interviews. Their analyses are 
published elsewhere.(10) In this paper, the data were analyzed using a thematic 
analysis approach, as it could capture the common beliefs and opinions of the sample 
while also recognizing unique experiences and perspectives.(80) An iterative coding 
process was used, which allowed the themes to develop over the course of the 
interviews, and ensured that the resulting themes were closely aligned with what 
participants said. 
Two members of the pharmacy research team (CW, AB) coded the first three 
interviews independently, with each researcher generating a list of codes. They 
compared their lists and resolved discrepancies through discussion and re-review of 
the pertinent data. One researcher (CW) analyzed the remaining 17 interviews, adding 
in new codes as they emerged. The second researcher (AB), who was present at all 
interviews, reviewed the final code book for accuracy and completeness. Inductive 
thematic saturation was reached on the basis of no new codes being observed in the 
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data.(81) While preparing the manuscript, the Standards for Reporting Qualitative 
Research (SRQR) were followed (Appendix C).(82) 
3.3 Results 
 The analysis identified four major themes. The themes encapsulate pharmacist 
perspectives on the current state of RFU communication, and pharmacist perspectives 
on the implications of adding RFU to prescriptions. 
3.3.1 Theme 1: Format for adding RFU to prescriptions 
 The pharmacist participants were asked the format in which they would like to 
receive RFU from prescribers, if they or the prescribers should be responsible for 
putting RFU into patient-friendly language, and the ideal format for adding RFU to a 
pharmacy medication label. Pharmacists generally noted that they would prefer to 
receive the RFU as text over some sort of diagnostic code, such as an ICD code. Most 
pharmacists indicated that they were not comfortable with the ICD system. As such, the 
use of these codes to communicate the RFU to pharmacists is a barrier to pharmacists’ 
uptake of using RFU in this format, as indicated by this participant: 
 
I would say there’s already so much to memorize in terms of [drug] entry. It 
would be great if the system already had pre-made indications already attached 
to a drug, and that someone doesn’t need to memorize like 100 codes like a 
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 Pharmacists expressed comfort with both medical and nonmedical language 
being used to communicate RFU. They generally indicated that both parties should be 
responsible for putting the RFU into nonmedical lay-language for the patient. Most 
pharmacists noted that nonmedical terminology should be used on medication labels, 
as this information would likely be of highest utility for patients. One pharmacist 
mentioned that both nonmedical and medical terminology should be included on the 
label, proposing the medication bottle be used as a tool for helping the patient 
understand the meaning of some medical terminology: 
 
If [the medication bottle is for] the patient, I think they should use lay terms with 
the medical term in brackets, because I think that sometimes healthcare 
providers still use the medical terms and it’s to [the patient’s] benefit to know 
that those things are equal to each other. [Pharmacist 14] 
3.3.2 Theme 2: Privacy implications of adding the RFU to prescriptions and labels 
All participants respected the need to protect patient privacy when RFU is 
communicated. Pharmacists, who see themselves and their staff as a part of the circle of 
care, emphasized the importance of all members of the healthcare team having access 
to RFU information to provide optimal patient care. All pharmacists indicated health 
information is as safe with them as with physicians. 
 
Everyone in their circle of healthcare team should be in the know, so that we can 
all work seamlessly together. I mean, it's as private with the doctor, as it is with 
the pharmacist. [Pharmacist 17] 
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Pharmacists generally indicated more concern with the addition of RFU onto 
medication labels, as this represents a public display of private health information. For 
pharmacists, this conflicted with their recognition that patients would benefit from 
having the RFU included on medication labels. Most pharmacists noted that they would 
not apply RFU onto a label without consideration of the diagnosis being communicated: 
 
…if it's a medical condition that might be a little personal and you don't want 
other people to look at it. For example, a sexually transmitted infection, then I 
wouldn't necessarily put it on the label. But sometimes if it's for more chronic 
medications like blood pressure or gout, diabetes, things like that, I would be 
more willing to put it on the label. [Pharmacist 09] 
 
The above pharmacist indicated the importance of the contextual information 
surrounding medications. Knowledge like how long a patient has been on a medication 
and how they are tolerating it can be best determined when there is a positive 
relationship between patient and pharmacist. Consequently, pharmacists noted that the 
addition of RFU onto medication labels for some indications should only be added in 
consultation with patients, and is a choice that must ultimately be left up to the patient: 
 
…if someone reads a patient's vial and the label indicates that they have 
depression… that could be a privacy concern, so that would potentially be a 
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3.3.3 Theme 3: Using RFU to assess medication safety 
Pharmacists acknowledged the benefits to patient safety when RFU if provided 
to both the pharmacists and patients in a written format. Many pharmacists noted that 
their ability to catch errors would be greatly improved with access to RFU. One 
pharmacist referenced a situation where a patient was prescribed a medication whose 
name was confused with a different medication: 
 
…this patient received hydroxyzine instead of hydralazine, and if the doctor had 
indicated the indication… somebody could easily check the prescription and 
think, "Okay, this medication was entered wrong." [Pharmacist 15] 
 
This error could have been caught more easily, or completely avoided if the 
pharmacist was provided the RFU. When there is uncertainty about the safety or 
appropriateness of a medication, the pharmacist must communicate directly with the 
physician, which is often a time-consuming task: 
 
Oh, [the RFU on the prescription] would definitely save time in regards to 
unnecessary questions back and forth between healthcare professionals. As 
much as we love to pick up the phone or always talk to the physician, they're not 
available. [Pharmacist 19] 
 
Another aspect of safety is that pharmacists can use the RFU during medication 
reconciliation to identify duplications in therapy or errors of omission. One pharmacist 
highlighted the breadth of information needed to help patients manage all of their 
medications: 
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… we can get bigger picture information like that that's lost between physicians 
or if [patients] were in the hospital. When they come to the same pharmacy, we 
have all this information. We have a better picture of everything, and there are 
things that get missed all the time. [Pharmacist 19] 
 
They summarized the opinions expressed by them and their colleagues as 
follows: 
 
[Providing written RFU to pharmacists has usefulness in] preventing errors, 
providing better healthcare, accelerating time in regards to being more efficient, 
double-checking with the physician so that the errors won't occur. [Pharmacist 
19] 
3.3.4 Theme 4: Using RFU to individualize counselling 
 Pharmacists universally indicated that RFU would be valuable and improve their 
ability to effectively counsel patients. Counselling involves bidirectional communication 
between pharmacist and patient, which is impacted by the nature of the diagnosis: 
 
It's good to know [RFU] so that when you approach your counseling you can be 
sensitive to the state of mind they might be in, right? …If it's [for] depression, 
you want to not go over, "Yeah! Hi! How's it going?" … You can just gauge your 
own counseling technique based on knowing [the indication]. [Pharmacist 02] 
 
Pharmacists currently guess RFU based on the medication and confirm the guess 
by asking the patient directly. This process can be uncomfortable for some medications 
indicated for more sensitive diagnoses: 
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Obviously, if I have a clear reason for use, I'll just tell them what it was. Then, if I 
don't have a clear reason for use, I'll say ... For example, an anti-depressant, if 
they are not forthcoming, for example, [with] the reason for use, I'll say, "Okay, 
this medication can be used for depression or sleep, and this is the dose you 
have, so I think it's [for depression]." [Pharmacist 18] 
 
This can lead to an uncomfortable dynamic between the pharmacist and patient.  
Erroneous assumptions can also occur when determining the RFU for medications with 
multiple indications: 
 
I got a patient with… a new dosage of Seroquel, but it was the least dose and he 
wasn't really cooperative [when] talking. …I told him “probably you're using it 
for sleep” because it was just the lowest dose… [it’s] only when he called [later] 
and revealed that it's for schizophrenia and not sleep. [Pharmacist 10] 
 
This situation required follow-up with the prescribing physician, as the dosage 
prescribed was not indicated for schizophrenia. Cases like this could be addressed more 
rapidly if RFU was provided to the pharmacist.  
A male pharmacist interviewed mentioned that this process of verifying RFU in a 
question format can be difficult for him, especially when working the overnight shift as 
the only pharmacist available: 
 
Sometimes when [working overnight shifts, I see some female patients filling] 
emergency prescriptions. Most of the time ... actually all the time I will ask the 
patient why they're using it. Sometimes I voluntarily tell them "You're taking this 
medication for this reason," just to make it easier with them, and they say, "Yes," 
and that actually creates some confidence between the pharmacist and the 
patient. [Pharmacist 13] 
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Here, a clear picture emerges of the pitfalls of prescribers not providing written 
RFU to pharmacists. Not providing pharmacists RFU can lead to poor patient 
experience, and the need to guess RFU can result in errors leading to patients receiving 
inaccurate and irrelevant information.  
3.4 Discussion 
 Pharmacists would directly benefit from receiving RFU, allowing them to assess 
medication safety more effectively, and to provide more sensitive counselling to 
patients. In this study, it was clear that RFU is valuable information that is currently 
missing from pharmacists’ workflows. Pharmacists in this study identified several 
discrete and relevant steps in their workflow where RFU would optimize patient care. 
This can include the use of RFU to assess the appropriateness of a medication dose, 
personalize patient education, and prevent look alike/sound alike drug name errors. 
 This paper joins the few prior studies which have directly engaged pharmacists 
in conversation on RFU.(73,76) The pharmacists interviewed for this study commented 
on the privacy considerations of including a medication’s indication on the medication 
label underscore the importance of respecting individual patients’ choices when 
deciding to add them. Despite the increasing body of literature strongly supporting the 
addition of RFU on medication labels, equal attention must be paid to when the addition 
of RFU on medication labels may be harmful to patients.(18) The pharmacists 
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interviewed indicated that RFU should only be added to medication labels while 
considering the broader context of the medication, including factors such as the 
sensitivity of the illness being treated by the medication (ie, if there is stigma 
surrounding an illness), if the medication is being used to treat an acute illness or 
chronic illness, and if the patient is taking multiple medications.   
 Many of the privacy considerations raised by the pharmacists interviewed 
revolved around adding indications to prescriptions and medication labels for 
medications to treat sensitive illnesses, such as STIs or mental health illnesses. When 
the topic of privacy was raised, all of the pharmacists readily suggested that consulting 
on a patient-by-patient basis could clarify if RFU should be added to the medication 
labels. However, a patient with dementia may not have the capacity to consent to the 
addition of RFU to their medication label, but this could aid their caretaker in managing 
their medications. Guidelines for the addition of RFU if the patient is unable to consent 
its addition on medication labels are needed, along with consultation from people who 
live with sensitive illnesses.  
 Pharmacists’ desire to receive RFU in a written format aligns with suggested 
changes in CPOEs to support indication-based prescribing.(9,53) Much work on 
indication-based prescribing includes the use of drop-down menus in COPEs, as 
opposed to free-form text entry. This is suggested to reduce prescriber task burden 
while writing a prescription, however this may not support the use of lay-language on 
medication labels.(53) Prescribers will need to be comfortable with pharmacists 
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including their own lay-language interpretation of the RFU on the medication label to 
facilitate its use as a patient education tool.  
 The pharmacists’ comments are all in agreement with the existing literature on 
the capacity for RFU to improve medication safety.(18) Comments on how RFU will 
improve counselling are all rooted in a desire to provide a comfortable environment for 
pharmacists and patients to discuss medications. Pharmacists indicated that knowing a 
medication’s RFU was especially important for sensitive illnesses and mood-altering 
illnesses. Psychiatric medications occupy both of these categories and can have multiple 
indications. Pharmacists would benefit from knowing psychiatric medications’ RFUs in 
particular but should consult with patients before including them on the medication 
label.   
 The pharmacists interviewed were all from a similar geographic region in 
Ontario and were all community pharmacists. This homogeneity means that 
pharmacists from regions with differing scopes of practice were not captured. The 
pharmacists interviewed did practice in a variety of settings, including family health 
team-based practice, chain, and independent retail pharmacies. To improve the 
trustworthiness of the analysis, a non-clinician researcher (CW) analyzed the data.  
 These results provide further impetus for the inclusion of RFU on prescriptions, 
and on medication labels, especially given the benefits to patient safety if RFU is 
provided on medication labels. Pharmacists are aware of the privacy risks of including 
this information on medication and are prepared to navigate these concerns in 
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consultation with patients. Future research will focus on the physician perspective. For 
physicians to fully embrace this, however, there will likely need to be computer system 
changes, regulations, and/or incentives put into place to ensure physicians are willing 
and able to share the indication as part of their daily workflow. Finally, pharmacists are 




Chapter 4: Prescribers’ perspectives on including reason for use information 
on prescriptions and medication labels: a qualitative thematic analysis 
4.1 Introduction 
Many North Americans use medications to treat illnesses and manage their 
health. In Canada, 66% and in the United States, 69% of adults aged 40-79 used at least 
one prescription medication in the last 30 days as found by the Canadian Health 
Measures Survey (2016-2017) and the US National Health and Nutrition Examination 
Survey (2015-2016), respectively.(1) Depending on the jurisdiction, medications can be 
prescribed by a number of clinicians, including physicians, physician assistants, nurse 
practitioners, optometrists, dentists and pharmacists, according to their specialty, scope 
of practice and appropriate legislation.(83) Prescribers rarely include RFU on 
medication prescriptions (also commonly referred to as the indication for use).(19) In 
an analysis of more than 4.3 million outpatient prescriptions issued between 2011 and 
2015 from a major academic medical centre in Illinois, only 7% of prescriptions 
included the RFU.(19) 
The addition of RFU to prescriptions can have positive impacts on medication 
safety, adherence and patient understanding of their medications by helping 
pharmacists understand medications when dispensing them.(9,24) Despite efforts by 
prescribers to educate patients about their medications, patients may still lack a clear 
understanding of why a particular medication was prescribed, which is associated with 
increased adverse drug events.(84) In the United States, Persell et al. showed that 
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patients belonging to populations associated with increased morbidity, namely those 
who are older, less educated, or black, are less likely to know their medications’ 
RFU.(49,83) However, pharmacists who have access to the RFU catch more medication 
errors, reduce unnecessary contact with prescribers, and reinforce physician education 
of patients.(33,73,74) Despite these and many other studies showing the value of 
adding RFU to prescriptions, along with support from various healthcare advocacy 
groups, prescribers must ultimately choose to add RFU to the prescriptions they 
write.(52,85) 
Much of the literature has focused on technological ways of making the addition 
of RFU more straightforward, and engaging high-level stakeholders in the value of 
adding RFU, however no studies have directly asked prescribers for their perspective 
on the addition of RFU on prescriptions.(9,18) From an implementation perspective, it 
is critical to understand its potential value for prescribers relative to the perceived 
impact on workflow.(41) The objective of this paper was to explore physician 
perspectives on writing medication RFUs on prescriptions and medication labels.  
4.2 Methods 
We conducted semi-structured interviews with 20 prescribers (2 nurse 
practitioners, 18 physicians) in Southern Ontario, Canada between June and August 
2018. The interviews were conducted as a part of a larger study evaluating how 
pharmacists, prescribers and patients currently communicate RFU, how policies around 
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RFU sharing may impact healthcare teams, and clinicians’ perceptions on sharing RFU 
with their colleagues and patients. Semi-structured interviews were used, as they 
allowed the flexibility to follow-up on key concepts mentioned by participants.(80) 
Ethics approval was received by a University of Waterloo research ethics committee 
(ORE# 31591).  
Prescribers in AB and KG’s networks and were asked to participate in this study. 
Upon completion, they were also asked if they knew any colleagues who may also be 
willing to participate in the study. This snowball sampling method was used to gather 
additional participants. Prescribers were interviewed at a time and location of their 
choosing, often over the phone or at their clinic. A $150 CAD honourarium was 
provided in appreciation for their time. Information on participants’ demographics, 
profession, specialty and years of practice was collected, and can be found in Table 3. 
Additional aggregated demographic information can be found in Table 4. 
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Table 3, Demographic profile of  prescriber participants  
 
ID Type Specialty Years in 
Practice 
Prescriber 01 Nurse practitioner - unknown 
Prescriber 02 Nurse practitioner - 9 
Prescriber 03 Physician Family medicine 20 
Prescriber 04 Physician Family medicine 32 
Prescriber 05 Physician Family medicine 30 
Prescriber 06 Physician Family medicine 8 
Prescriber 07 Physician Family medicine 33 
Prescriber 08 Physician Family medicine 1 
Prescriber 09 Physician Emergency medicine 4 
Prescriber 10 Physician Family medicine 29 
Prescriber 11 Physician Emergency medicine 5 
Prescriber 12 Physician Emergency medicine 4 
Prescriber 13 Physician Emergency medicine 4 
Prescriber 14 Physician Family medicine 7 
Prescriber 15 Physician Emergency medicine 5 
Prescriber 16 Physician Family medicine 2 
Prescriber 17 Physician Family medicine 2 
Prescriber 18 Physician Family medicine 2 
Prescriber 19 Physician Anesthesiology 7 
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Table 4, Practice details for prescriber participants  
 
Demographic Type Demographic Information 
Recruitment method Personal network: 7 
Snowball sampling: 13 
Practice type Community health centre: 4 
Family health team: 4 
Hospital: 7 
Independent practice: 5 
Practice location Southwestern Ontario: 14 
Greater Toronto Area: 6 
Academic appointment Adjunct appointment: 4 
Full appointment: 3 
None: 13 
 
4.2.1 Data collection 
Interviews were conducted by one pharmacy and one systems design engineering 
researcher using a semi-structured interview guide jointly developed by the 
engineering and pharmacy teams (Appendix D). Feedback from prescribers and 
patients was sought in when developing these questions. Specifically, we used a 
qualitative approach to ask prescribers the following: 
• how their practice and clinical workflow would be impacted by being required to 
add RFU onto prescriptions; 
• how sharing RFU information on prescriptions would impact their relationships 
with other prescribers, pharmacists and patients, and; 
• the perceived impact of having RFU information shared on patient medication 
labels. 
 
Interviews were recorded and transcribed. In the interviews, prescribers were 
asked about their current clinical workflow and how RFU fits into it, changes to 
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workflow as a result of adding RFU, and how adding RFU could impact professional 
relationships with clinicians and patients.  
4.2.2 Data analysis 
Transcripts were stored and analyzed using NVivo 12 for Mac.(79) Thematic 
analysis allowed for prevalent participants’ opinions to be expressed while preserving 
unique perspectives.(80) Iterative coding allowed themes to develop over the course of 
reviewing the interviews and ensured that the final themes were aligned with what 
participants said. 
Two members of the pharmacy research team (CW, KG) coded the first three 
interviews independently and generated a list of codes. Differences in coding were 
reviewed for each interview, and discrepancies resolved code-by-code. Both CW and KG 
reviewed the remaining interviews and met periodically to review codes and resolve 
discrepancies, by discussing the rationale for particular codes. Through this process, the 
codebook was updated as new codes emerged, upon the agreement of both researchers. 
CW and KG assembled the quotes into larger themes, and the quotes were synthesized 
into a Framework Matrix using NVivo 11 for Windows. Quotes in the Matrix were 
reviewed, and representative and divergent quotes were selected for our results. The 
final analysis was reviewed by a physician researcher to provide additional background 
and context. Memos were periodically written during the coding process, to facilitate 
theme generation and refinement. The engineering team separately analyzed the data, 
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and developed a model of prescriber decision making, which is published 
elsewhere.(10) 
4.2.3 Saturation 
Code saturation is claimed for these interviews on the basis of the information 
weighting (IW) model presented by Lowe et al.(86) This method of determining code 
saturation relies on a number of numerical values determined as interviews are 
analyzed and are suited to the a posteriori analysis used in this study, where analysis 
occurred after the interviews were conducted. The information weighting model allows 
qualitative researchers to calculate the expected total number of codes and expected 
percentage saturation for a given population of known characteristics being 
interviewed. For example, as prescribers would generally have similar experiences 
determining why a patient was prescribed a medication from another prescriber, 
prescribers could be said to be part of a single population. 
The twenty interviews were analyzed in a random order determined by a 
random number generator, and the following values were determined from the first 
three interviews in the randomized list: 
Number of interviews considered for model, 𝑁 = 3  
Number of codes in first interview, 𝐶1 = 19  
Number of codes in the first three interviews, 𝐶3 = 23  
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which, when entered into the IW model, resulted in: 
Percentage saturation, 𝑃 = 0.98   
Estimated total number of codes , 𝐶𝑛,𝑒𝑠𝑡 = 25  
 
The model estimated that 25 unique codes would be observed in the interviews, 
and a total of 25 codes were observed. As new codes were added to the code list, 
interviews were re-analyzed using the new codes. P and Cn,est were calculated only after 
all of the interviews were analyzed, so that the results of the model would not influence 
new code creation. Based on this model, there are no new codes that could be observed 
from the data. Additionally, inductive thematic saturation was reached on the basis of 
no new codes being observed in the data.(81) While preparing the manuscript, the 
SRQR was followed.(82) 
4.3 Results 
Twenty prescribers (18 physicians, 2 nurse practitioner) were interviewed. 
Participants included the following specialties: 12 family medicine, 5 emergency 
medicine, and 1 anesthesiology. Additional information can be found in Table 3, and 
aggregated demographic information can be found in Table 4. 
Most of the prescribers acknowledged that adding RFU onto their prescriptions 
would take additional time and result in some additional workload. However, the 
prescribers also generally acknowledged that there would be benefits to their clinical 
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practice. These aspects are captured in the following four themes: current practice; 
future practice; changing culture; and collaboration.  
4.3.1 Theme 1: Current Practice 
Throughout the interviews, prescribers were invited to comment on their 
current practice with respect to RFU, and how they thought pharmacists were currently 
determining and using RFU to dispense the prescribed medications. Most prescribers 
interviewed indicated that they do not generally add RFU onto prescriptions, with some 
exceptions. For example, one prescriber indicated that they add RFU in two situations:  
 
Mainly [adding RFU] for PRNs, more than likely for medications that might be a 
short-term use for a new indication. That might be the time you might [add the 
RFU]... or particularly with an older person. [Prescriber 04] 
 
When asked to speculate on how pharmacists currently obtain RFU, the 
prescribers believed that pharmacists ask the patients, or guess. However, they 
repeatedly acknowledged that patients can be unreliable sources of information. The 
prescribers themselves acknowledged the dissonance between their expectation that 
pharmacists receive accurate RFU from patients, and their experiences with patients 
not understanding aspects of their own care: 
 
[Pharmacists] might ask the patient. Patients might not always know, we know 
that. … But certainly there's going to be a lot of confusion … I would imagine that 
most [pharmacists] have so much experience dealing with [prescribers] that 
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they understand, probably, what's going on, but that's not a good explanation. 
[Prescriber 06] 
 
This prescriber noted that pharmacists appear to be generally competent at 
using context and experience to determine the RFU. But as the prescriber noted, this is 
not a good replacement for clear interprofessional communication. While the 
prescribers generally believed pharmacists could benefit from the information, there 
was a concern that not all pharmacists would make good use of it: 
 
Large pharmacies like [national pharmacy chain], I don't think patients get a lot 
of counseling 'cause I think they're turning a lot of prescriptions, whereas my 
experience with smaller, community pharmacists is that the patients get a lot 
more information, and they get some information to help them understand why 
they were prescribed that medication. But I don't think it happens consistently. 
[Prescriber 10] 
 
4.3.2  Theme 2: Future Practice 
Prescribers were asked what they thought of adding RFU into region-wide drug 
database, such as an electronic health record or a drug profile viewer. They were 
generally supportive of allowing their colleagues to access information as to why a 
medication was prescribed.  
 
I don't know why [a medication’s RFU] should be [a secret]. I think [having it in a 
regional database] would be good.” [Prescriber 2] 
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But they were quick to note that having the opportunity to add context to the 
prescription would be beneficial. 
 
 … having that free-form box would be useful because sometimes the diagnosis is 
not always clear, so you have room to say ‘viral [upper respiratory infection] 
ruled out otitis media versus strep’ something like that. [Prescriber 2] 
 
The notion of saving time on call backs from pharmacists was cited by a number 
of prescribers as one of the greatest strengths of adding RFU, with the following quote 
reflecting the opinion of a number of prescribers: 
 
…[S]ometimes pharmacists send us notes back asking for clarifications, so 
there'll be time saved in not having those faxes of clarification. [Prescriber 10] 
 
In general, prescribers were mostly in agreement that they did not need support 
in adding RFU to prescriptions, despite the increase in work. Some prescribers 
mentioned that since they already knew the indication, the only difference from current 
prescribing practice would be writing down what they were already thinking.  
 
I don't know why [prescribers] would need help to document the reason for use, 
because [they’re] prescribing [the medication] for a reason. [Prescriber 9]  
 
However, many prescribers were wary of the impact that adding this task would 
have on their overall workflow.  
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The only concern I would have, is that it will just take an extra few minutes. 
[Prescriber 14] 
 
Most prescribers who expressed concern about the impact of adding RFU on 
their workflow cited a similar issue: their concern with adding RFU is primarily in the 
cumulative time spent entering indications in their EMRs, which could take away from 
time spent with patients. As one prescriber described: 
 
…for meds that are being prescribed on a regular basis, once you put it in the 
EMR once, and you go to refill that med, it's gonna pop up, Reason for Use. So, it’s 
just a little bit more work up front. But I think it would be worth the effort, 
ultimately, at the end of the day given the benefit. [Prescriber 14] 
 
However, one prescriber in particular felt that the time required of prescribers 
to add RFU to every prescription would be too great, and that a targeted approach in 
adding RFU only in situations where clarification would be of high utility was suggested. 
Situations cited by the prescribers interviewed as benefiting from the addition of RFU, 
as well as those where RFU should not be added are presented in Table 5. 
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Table 5, When to add RFU according to prescriber participants  
 
Add RFU Do not add RFU 
• Older adults 
• Antibiotics for paediatric patients 
• Polypharmacy 
• Unusual dose or indication 
• Persons who need supports to take 
medications 
• As needed (PRN) medications 
• Medications for acute conditions 
• Treatment for sensitive illnesses 
(eg, STIs, psychiatric medications) 
• Adding RFU increases patient’s 
anxiety 
• Could affect patient's likelihood of 
taking the medication 
• Off-label prescribing 
 
4.3.3 Theme 3: Changing Culture 
Prescribers readily admitted that their training did not make them aware of the 
value of passing along RFU to pharmacists, but most could identify potential benefits 
when asked. While the goal of this study was not to influence prescriber behaviour, the 
mere act of asking prescribers how this information could be useful to pharmacists 
encouraged a number to consider adopting this more collaborative practice.  
 
… I think it's a really good idea, and I never really thought about it and how 
important it is until today. May start doing it. [Prescriber 16] 
 
In contrast to Prescriber 16, a different prescriber shared similar sentiment, but 
much more reservedly: 
 
I guess the one thing that would be important before going forward with making 
something mandatory, I feel like a lot of doctors get nervous, or they don't like 
hearing about more mandatory stuff. And I understand, again, death by a 
thousand cuts, so it would be important to make sure that doctors, maybe the 
[medical associations], or whoever is in charge of doctors, weighed in and really 
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felt comfortable and felt like they were on board with adding more responsibility 
to what doctors do. But I do think overall it sounds like a good idea. [Prescriber 
11] 
 
Prescribers may feel that some aspect of their autonomy in prescribing may be 
threatened if the inclusion of RFU is mandated without appropriate consultation. While 
many prescribers welcomed the additional set of eyes verifying that the prescribed 
medication was correct for the specific indication, others were concerned that routinely 
providing RFU to pharmacists may cause interprofessional conflict and could ultimately 
result in patients not taking their medications: 
 
If the pharmacist disagrees [with my indication] then I really don't, as a 
physician, who has seen the patient and have spent some time with them, and 
have gone through their history; I would hate for that aspect of the care to be 
challenged and the patient not going on the medication… [Prescriber 19] 
 
Prescribers also generally preferred the idea of a free text entry field for adding 
RFU, allowing them the flexibility to be precise in their documentation. Some of the 
prescribers mentioned the possibility of suggested RFU options within the EMR, 
integrated similar to an “autocomplete” function.  
4.3.4 Theme 4: Collaboration 
Prescribers were asked to comment on how listing RFU on prescriptions and 
medication containers would impact their relationships with other prescribers, 
pharmacists and patients.  
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With respect to their relationships with other prescribers, the prescribers 
interviewed noted that they would benefit from having ready access to RFU any time 
they had to understand why a patient was prescribed a particular medication (eg, after 
a visit to a different prescriber or when a prescriber takes over an existing practice). 
They also generally agreed that a regional EHR or a medication label was the best and 
most convenient place to store this information for easy access. Few prescribers noted 
that their relationship with other prescribers would be impacted, but they generally 
agreed that ensuring other prescribers had access to this information would facilitate 
communication across the healthcare team: 
 
I think it would enhance the relationship [between prescribers] because 
everyone is clearer and on board as to why you prescribed something for what 
reason. [Prescriber 10] 
 
A small minority of prescribers noted that adding this information could lead to 
“judgement” [Prescribers 16, 19] from their colleagues. Specific cases that were noted 
included if the other prescriber is not used to an indication being written in a particular 
way, or if the other prescriber lacks some contextual information surrounding the 
prescription.  
Prescribers were also asked to comment on whether it would be useful to have 
access to a patient’s RFU for a medication when they did not prescribe it. They 
overwhelmingly had confidence in their ability to infer the prescriptions’ indications 
based on the medication list.  
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[When looking at a medication list] I probably don't need a lot of information [to 
determine RFU]. Cause I can look at the medication list and kinda understand 
what they're there for. [Prescriber 7] 
 
With pharmacists, prescribers readily noted benefits such as an increase in 
bidirectional communication, supporting deprescribing, checking medication doses for 
a given indication to improve safety, improving counselling and patient education, and 
improving adherence. However, one prescriber expressed the following concern about 
the trustworthiness of pharmacies: 
 
I mean, the only, my only concern about that would be if that information is 
being used for commercial purposes... You know, like say someone comes into a 
[national pharmacy chain] with an STI. Is [national pharmacy chain] now going 
to target them with advertisements to get them to buy more condoms? 
[Prescriber 15] 
 
This prescriber’s concern reflects the importance of ensuring all parties 
understand how this information may be used, and the need to support patient 
confidentiality when sharing information between clinicians.  
With regards to relationships with patients, prescribers tended to be either 
positive or ambivalent about the potential impact of adding RFU on prescriptions. All of 
the prescribers noted that they explain to patients why a particular medication was 
prescribed. Some prescribers noted that benefits may not be experienced by all patients 
when adding RFU: 
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So, for some people, it may be a very helpful thing. It may help them to 
understand their medications a little bit better to make more informed users, I 
suppose. For others, it may just be not necessary information that they already 
knew. [Prescriber 4] 
 
Others presented a view in light of their own experiences with the information 
patients know. 
 
I feel like writing something down gives the patients something concrete, 
because I often end up writing things down for them anyway, so this way they 
have it already on their prescription. I feel like it gives them something concrete 
that they can go Google when they get home. [Prescriber 11] 
 
The prescribers all acknowledged that patients have the right to know why they 
were prescribed a given medication, and generally agreed that providing written RFU 
would support patients in understanding their medications.  
4.4 Discussion 
The prescribers interviewed were supportive of improving their communication 
with their pharmacist colleagues, especially because of the potential to support patient 
education and safety and to save time via reduced call backs about prescriptions. The 
potential increase in workload caused concern for most prescribers, but they did not 
feel they would need assistance in adding RFU to prescriptions. The few prescribers 
who currently add RFU to prescriptions tended to do so in limited circumstances, which 
seemed to be a palatable option for most prescribers. Prescribers’ speculation that 
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pharmacists currently determine RFU by asking the patient, or by guessing is in 
agreement interviews that we conducted separately with pharmacists, and many 
participants empathized with the difficulty their pharmacy colleagues have in 
determining why a given medication was prescribed.(87) 
Considerable research is being done to design electronic medical records that 
support indication-based prescribing. The work by Schiff et al., for example, is focused 
on having prescribers first identify the indication and then select from a list of 
recommended therapies.(9) This paper, however, focuses on whether that information 
should be shared with pharmacists. Most prescribers interviewed reported they had 
never considered the difficulty faced by pharmacists when dispensing a medication 
when they did not know why it was prescribed. To promote the routine addition of RFU 
to medication labels, the utility of RFU in ultimately saving the prescriber time as well 
as the benefits to their pharmacist colleagues should be emphasized to ensure maximal 
uptake of this burden on prescribers.(33,87) 
Participants were asked to reflect on how their relationships with other 
prescribers, pharmacists and their patients would be impacted by the addition of RFU. 
Few prescribers focused on these professional relationships, but they highlighted that 
adding RFU would likely lead to improved communication with other prescribers and 
pharmacists. When sharing RFU with pharmacists, some of the prescribers expressed 
concern about possible interprofessional conflict that could result if a pharmacist is 
critical of a prescription, which has been found to be a considerable source of stress for 
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pharmacists.(43) While much of the RFU work has focused on time constrains, attention 
must be paid to the skills needed for interprofessional teamwork. In terms of 
relationships with patients, the value of leaving an appointment with a tangible 
document with their medication name and RFU included was noted, though the benefits 
may be lessened by the adoption of ePrescribing.(69)  
Throughout the interviews, the prescribers highlighted a number of cases where 
adding RFU would be particularly beneficial. If adding RFU is to be implemented in 
routine practice, phasing in its use beginning with select populations or medications 
may help to highlight the value of this practice to prescribers, help clarify expectations 
for the parties involved, and provide valuable information to pharmacists.(87) 
Additionally, piloting the addition of RFU in select teams in a healthcare organization 
could both generate additional evidence for its value, but also promote more ready 
uptake of this prescribing practice.(88) Future work will focus on developing guidelines 
for when RFU should be added to prescriptions and medication labels, and consulting 
with communities who live with sensitive illnesses to determine what they would see as 
best practice for sharing the RFU for their medications on prescriptions and medication 
labels.   
4.4.1 Limitations 
This study sampled a limited number of prescribers in one geographic region in 
Canada, representing two types of prescribers (physicians and nurse practitioners) and 
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three medical specialties (family medicine, emergency medicine, and anesthesiology). 
Some practitioners in the specialties interviewed (eg, emergency medicine, 
anesthesiology) may not provide routine follow-up with patients, resulting in limited 
context regarding the impact of pharmacy practice on medication therapy management. 
Finally, gaining perspectives from other clinicians (eg, dentists, optometrists), including 
those providing treatment in inpatient settings, and in other locations would enhance 
the transferability of these findings. 
4.4.2 Conclusion 
This study highlights the aspects of RFU addition that may cause friction for its 
routine use, however it highlights a number of beliefs expressed by prescribers that 
should be used in implementation efforts. These results can be used to advocate for a 
staged rollout of RFU for select prescription classes/populations, and to support the 
implementation of new workflows such as indications-based prescribing. By keeping in 
mind the concerns of these prescribers as the push to routinely include RFU on 
prescriptions continues, increased interprofessional communication, increased patient 
understanding of their medications, and decreased harm from the use of medications 
can be achieved. 
 
  59 
Chapter 5: How do I keep myself safe? Patient perspectives on including 
reason for use information on prescriptions and medication labels: a 
qualitative thematic analysis  
5.1 Introduction  
Medications are fundamental for the maintenance of good health and the 
treatment of disease in modern medicine. In Canada between 2007 and 2011, 41% of 
people living in the community between the ages of 6 and 79 took at least one 
medication, and around 30% of 65 to 79 year old people took 5 or more medications 
(ie, polypharmacy).(89) With adverse drug events causing more than 27,000 
hospitalizations in Canada between 2010 and 2011, the safe prescribing and use of 
medications, as well as improving clinician-clinician and clinician-patient 
communication around medications represent key areas for health systems to facilitate 
safe medication use.(90) One such aspect is the addition of medication indications, also 
known as RFU, onto prescriptions and medication labels.  
Patients are increasingly being asked to manage many aspects of their care, 
including communicating health information between healthcare providers and 
maintaining records of their own health.(42,55) Numerous studies have indicated that 
patients are sometimes unaware or incorrect about why they are taking a particular 
medication.(84,91) Adding RFU to medication labels would allow patients to always 
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Prescribers have identified barriers to the addition of RFU on medication labels, 
including the time required to add indications when writing a prescription, uncertainty 
of how to format the information, and being unsure of the value of adding RFU to 
prescriptions.(92) However, they acknowledged potential time savings in including RFU 
by pre-empting concerns from pharmacists.(92) From a pharmacy perspective, 
pharmacists have indicated that they would be able to more effectively carry out their 
clinical duties if provided RFU on a prescription and would ultimately benefit from 
being provided RFU on prescriptions, with previous studies determining that having 
access to RFU helped to nearly double the number of prescribing errors detected by 
pharmacists.(32)  
Previous studies have investigated the perspectives of patients in adding RFU, 
many of which identified similar concerns to the prescribers and pharmacists 
above.(42) A systematic review on medication labels indicated that the labels facilitate 
communication and comprehension about medications by patients, and medication use 
errors may be caused by poor medication labels.(93) Additionally, medication labels 
designed to be more patient-friendly have been shown to improve adherence in 
patients with low literacy, as well as on medications that need to be taken two or more 
times per day.(75) Through these studies, however, a clear understanding of how 
patients themselves may use RFU was not determined. Thus, the objective of this paper 
is to describe patients’ perspectives on the usefulness of adding RFU information to 
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prescriptions and prescription labels, and how they may use RFU to make decisions 
about their medications. 
5.2 Methods 
Semi-structured interviews were conducted with 20 community members who 
have used at least one medication in the last 30 days. Patients were recruited via flyers 
posted in public places, including the local university, doctor’s offices and pharmacies. 
Patients were also recruited using an institutional database of older adults who 
indicated an interest in being contacted about research studies.(94) All participants 
were from Southwestern Ontario, and were interviewed at a time and place of their 
choosing. Semi-structured interviews allowed for flexibility on the part of the 
researchers to follow up on statements and themes mentioned by participants.(80) This 
study was approved by a University of Waterloo research ethics committee (ORE# 
31591). Participants were asked questions about how they organize information about 
their medications, their comfort with having RFU communicated to pharmacies, and 
their thoughts on having medications’ RFU on medication labels. A $25 CAD 
honourarium was given to participants in thanks for their time. Information on 




Table 6, Demographic profile of  patient participants  
 
Demographic Type Demographic Information 
Age Young Adult (15 to 24 years): 1 
Adult (25 to 59 years): 7 
Older adult (60+): 12 





5.2.1 Data collection 
Interviews were conducted by two pharmacy and one systems design 
engineering researcher, using a semi-structured interview guide (Appendix E). This 
interview guide was developed by the pharmacy and systems design engineering teams, 
with input from patient partners. The interviews were recorded and transcribed.  
5.2.2 Data analysis 
NVivo for Mac was used to store and analyze the interviews.(79) Thematic 
analysis was used for the analysis, due to its flexibility in capturing both major themes 
and deviant cases across the interviews.(80) Pharmacy researchers CW and KG 
analyzed the first five interviews and developed a working code book. Differences in the 
codes created, as well as the codes applied in the specific interviews were resolved. CW 
and KG discussed codes and additions to the code book every subsequent 5 interviews 
analyzed. Codes were then organized into broader themes separately by CW and KG. 
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CW selected the final themes and codes in collaboration with KG, and a Framework 
Matrix was generated using NVivo 11 for Windows. The Matrix was used to select 
quotes for inclusion in the themes, where quotes expressing the majority’s opinion as 
well as divergent cases were included. CW wrote memos throughout the interview 
analysis process to make note of key quotes and themes as they developed. Inductive 
thematic saturation is claimed on the basis of no new codes emerging.(81) The SRQR 
was followed during the preparation of this manuscript.(82) 
Participants were also asked to participate in an activity to redesign a 
prescription label. Those results, as well as data from some of the interviews are 
published elsewhere.(11) 
5.3 Results 
Patients generally acknowledged the value of providing pharmacists with RFU 
and having RFU on prescription labels, while acknowledging that including RFU on a 
prescription label may pose a privacy risk.  
5.3.1 Theme 1: Patient decision making with RFU 
Patients framed their understanding of RFU as the reason a medication was 
prescribed (ie, to decrease my blood pressure), as opposed to what it was treating (ie, 
hypertension). The notion of prescribers explaining the rationale for a medication’s use 
was reflected in patients valuing RFU in helping them make decisions regarding the use 
of the medication.  
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For example, patients might use RFU to know if they are using medications 
correctly.  
 
I would say that the biggest implication is not using it correctly. I know with the 
cream and with just some other things when I was trying migraine corrections, 
when I don't know why and I don't exactly know the "how" and the reason why 
it's important to take it at the same or anything, I would take it incorrectly and 
then it wouldn't have the desired effect. [Patient 006] 
 
As well, others used RFU to make decisions regarding the continued use of a 
medication: 
 
Well, you would know how important it was. You wouldn't want to skip doses if 
it was something very vital. [Patient 012] 
 
And to understand whether a medication was working: 
 
If your symptoms get worse, or your overall condition changes, you can kind of 
use your discretion on whether you should continue using it or not instead of 
having to go to the doctor each time. [Patient 005] 
 
In all of these cases, providing RFU in an easily accessible manner would allow 
the patient to make more informed decisions about their care, and help differentiate 
medications if RFU was included on a label. One patient described how they currently 
draw symbols on their medication labels to tell them apart: 
 
… having a label that would say use this for this or this for that, would make 
sense to me to have that on it. I truthfully, when I'm getting prescriptions, I put 
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them in my medicine cabinet and I will on my Luvox, my antidepressant, I put a 
happy face on it. Or on the Celebrex, I just mark on it bones. [Patient 020] 
 
Additionally, having RFU on medication labels would also be helpful for 
instances where there is a change in the brand of medication dispensed. One patient 
described their frustration with medication information receipt as a way to organize 
RFU as follows:  
 
…over the years, the [drug store] changed, maybe to a different brand, and the 
name changes. So if I look at my original [medication slip] I don't know what the 
new ones are. [Patient 015] 
 
Finally, patients appreciated that having RFU along with a medication name 
would allow them to learn additional information about their medication online: 
 
…when [my family doctor] gives me prescriptions he explains to me at the time 
why he is giving me something and what it should do for me. I then go online and 
look out to see what the side effects might be. [Patient 020] 
5.3.2 Theme 2: RFU in modern, patient-centered care 
Patients were asked to reflect on times they did not know the RFU for their 
medications. Some older participants recounted anecdotes like the following: 
 
When I was younger, the doctors just prescribed stuff and you accepted what 
they said without question. That was the mentality of the time, the doctor was 
this all-powerful all-knowing figure, and you were just the consumer of his 
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In accordance with practices relating to patient-centered care, this mentality has 
shifted to acknowledging patients as partners in care. One participant, a retired nurse, 
succinctly described the value of RFU to patients: 
 
If [adding RFU] were to be implemented across the board, I think it would… give 
people the opportunity to ask the “whys” and it would give them opportunities 
to find out more about the medications they're on. [Patient 007] 
 
When asked to rate the importance of receiving RFU from their prescriber, 19 of 
the 20 patients rated it at least a five out of five, with a number of patients rating the 
importance as more than five out of five. All of the patients interviewed expressed a 
desire to have a deeper level of understanding of their medications, for example 
understanding their physicians’ decision-making process: 
 
Well, I want to know that my doctor understands why he's prescribing this drug. 
Whether he's prescribing it for its mainly intended use, or whether it's for an off-
label use… I think patients these days want to be more proactive in their own 
healthcare. [Patient 017] 
 
Patients were on-board with RFU being shared with pharmacists, and many 
reported receiving varying levels of counselling from their pharmacist, ranging from 
quick check-ins for repeat prescriptions, to yearly comprehensive medication reviews.  
 
I have no problem with [reason for use information being shared with my 
pharmacist on every prescription] because, to me, [both pharmacists and 
prescribers] are providing a professional service, and the more they're talking, 
the better… for everybody. [Patient 014] 
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Additionally, the majority of the patients reported that at least one family member was 
aware of why they were taking their medications. 
 
Well, I would think your husband or wife should know, and if your children are 
around, if they're adults they should know. But I don't think the whole world 
needs to know. [Patient 013] 
 
All patients were able to note some benefits of adding RFU to medication labels. 
These included helping patients with polypharmacy manage their medications [Patient 
007, 014], providing information to others in emergency situations [Patient 006, 010, 
011, 015] and distinguishing medications from each other [Patient 001, 016]. 
Additionally, patients identified situations where other people are responsible for 
medication administration [Patient 013, 014, 017], and for older adults who need 
support [Patient 014, 019] as other times when having RFU on medications would be 
particularly valuable. Regarding emergencies, one of the participants shared the 
following: 
 
Well, I think in an emergency situation, it would be good for somebody if they 
saw [the RFU on my medication’s label]. Especially if…  they found it in my purse, 
then they would know, okay yeah, she's been taking this for X number of years. 
[Patient 011] 
 
Inversely, patients also readily identified a number of potential disadvantages to 
adding RFU medication labels, including other people potentially seeing the RFU 
 
  68 
[Patient 003]. This included including stigma surrounding STIs or psychiatric illnesses 
[Patient 007] illnesses one does not wish to disclose to others (ie, family) [Patient 013], 
and the potential for teenagers to bully each other as a result of RFU information 
[Patient 019].  
5.3.3 Theme 3: Logistical aspects of communicating RFU 
When asked, patients readily provided a number of methods they use to 
organize information related to their medications, Table 7. To organize their 
medications, most patients reported either keeping a list, or keeping the indications in 
their memory.  
 
Table 7, Ways of organizing medication-related information 
 
- A notebook with all medical-related information 
- A list of medications (mentioned by a majority of patients) 
o  one patient mentioned keeping it in their first-aid box 
o  another, in triplicate, one with them, two at home 
- Keeping the medication bottles in one place 
- Remembering it (mentioned by a smaller number of patients) 
 
 
When asked about the prospect of adding RFU to a medication label, the majority 
of participants agreed with the idea of adding RFU to medication labels. A number of 
patients specifically noted the value of adding the RFU close to where the directions are: 
 
I think it should be right under where the instructions are of how to take it. The 
average person doesn't want to know exactly the name of the prescription, they 
may not understand what the name of the drug is. [Patient 017] 
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Patients were asked how they wanted RFU to be presented in terms of the 
language used. Patients preferred that RFU be presented in a way that respects their 
knowledge and understanding of medications. For some patients, this meant lay 
language: 
 
Just tell me straight up… Just not technical stuff, not technical. [Patient 010] 
 
And for others, more medical language: 
 
…I'm a public health major and I told [the doctors I am comfortable with medical 
language], so they were able to say, what is calcification and hypertension, and 
even words like ... embolization and embolization processes, 'cause it's one of the 
surgeries I could opt for. I know what that is, so they were very comfortable just 
using textbook words with me. [Patient 001] 
 
Patients stated they expected that the RFU would be between one word to one 
sentence in length. “As brief as it could possibly be,” as Patient 018 put it.  
When presented with the option of accessing information about their 
medications using a web-based system (eg, website, mobile app), patients had mixed 
feedback. One patient discussed their perception of how frustrating managing login 
information for different systems could be: 
 
…[if one system] connect[s] to hospital, I might use a [Medical Record Number], I 
might use a hospital ID, and it's usually not the same for each hospital. For me, 
with so many specialists at different hospitals, I could just imagine it being a 
mess. Maybe I use the wrong ID for the wrong hospital, then and I get frustrated. 
[Patient 001] 
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Similarly, a different patient was concerned with different pharmacies using 
proprietary systems that do not allow information to be transferred between 
pharmacies: 
 
The concern I have with an app is that because I have to move around 
occasionally as I'm not always convinced that the pharmacy will be connected to 
the right app. Then I'd have to have multiple apps so I find that a bit more 
burdensome…. unless [there] was a third-party system that all pharmacies were 
forced to be on I guess. [Patient 002] 
 
Likewise, privacy concerns were raised by some participants who were afraid 
that their PHI would be accessed by unauthorized users: 
 
…because it's too easy to access by people who want to pry for nefarious 
reasons. [Patient 008] 
 
However, the idea of using a web-based system to access information about 
medications was generally regarded as an attractive option, exemplified by this 
participant’s viewpoint as an older adult: 
 
I think as the boomers age, more and more of that's going to be possible because 
we're becoming more and more tech savvy. And if I don't understand, I can ask 
my nine-year-old grandson who will tell me. [Patient 007] 
 
 
  71 
5.4 Discussion 
In the interviews, patients considered the RFU to be the rationale behind 
prescribing the drug. This information is useful for patients to help make decisions 
around medication use, such as knowing which medications would treat which 
symptoms, or determining when a medication could be stopped. Patients also felt that 
the RFU could them to help organize medication-related information, work with others 
such as family members to manage their medications or communicate with emergency 
medical personnel. In contrast, in prior research, pharmacists saw RFU as a tool to 
assess medication safety, and physicians saw it as a tool support interprofessional 
communication (ie, to decrease the number of clarifying calls from pharmacy), and to 
provide transparency around why a drug is prescribed.(87,92) Of note, no singular 
terminology or definition (ie, indication vs RFU) about what a clinical indication is or 
what information it needs to carry exists.(9) Indications listed on medication bottles 
should facilitate use by patients for decision making, as well as being of utility for 
clinicians to facilitate information transfer. However, like the pharmacists and 
physicians interviewed previously, the patients interviewed expressed concerns about 
privacy if someone saw RFU on a prescription label.(87,92) 
Many of the older participants noted that how their physician communicates 
with them has changed over time, representing a shift to patient-centered care. 
Communicating RFU represents a change in how information was communicates 
previously.(95) However, given the gap between clinicians’ and patients’ understanding 
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of what RFU is, clinicians will need to work alongside patients to ensure that when a 
medication is prescribed, information pertaining to both the symptoms and diagnosis 
are communicated clearly to patients. Increasing the accessibility of RFU is 
complimentary to current patient medication safety initiatives, including Canadian 
Patient Safety Institute’s #ConquerSilence and Five Questions to Ask about your 
Medications campaigns to increase transparency and information sharing about 
medications.(57–59) Additionally, it directly aligns with a number of guidelines from 
the Institute for Safe Medication Practices, including their Guidelines for Standard Order 
Sets, and published strategies to mitigate errors associated with look- and sound-alike 
medications.(96–98) 
Patient participants generally agreed that using lay language to communicate 
RFU information would be preferable to medical language, which aligns with existing 
work in this area.(42) Additionally, all participants were able to determine a situation 
in which having RFU written on medication labels would be valuable. Many of these 
were situations were where the RFU would be interpreted by a third party, and in a 
number of the cases, a person without medical training. Given this context, writing RFU 
in lay language on medication labels would provide the most utility in the broadest 
number of situations, allowing patients, family members and others to understand what 
a particular medication is for, and for clinicians to interpret the indication accurately.  
The idea of having a patient-facing website or app was also attractive to most 
participants, so long as it was straightforward to access. Many participants reported 
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they currently use lists to manage their medications; a patient website or app is similar, 
just in a digital format. Reducing friction in the sign-in process could help facilitate the 
adoption and uptake of a website or portal for patients’ use but would not accomplish 
all of the goals of having RFU written on medication bottles, especially to allow others 
to determine RFU.  
Extensive work has been conducted in the area of RFU improving safety, like the 
work of Bosch-Lenders recommending the addition of RFU on medication labels to 
support older adults safely using medications, and to improve patient 
adherence.(42,99) The latter study by Garada, Schiff et al. involved researchers 
interviewing patients regarding the use of putting RFU on medication labels indications 
as well. Additional work by Schiff et al. has examined the addition of medication 
indications via “indications-based” prescribing to allow for easier and faster addition of 
medication indications, to enhance medication safety and to improve clinician 
communication.(18,42,53)  This paper builds on their existing work by highlighting 
some additional benefits to adding RFU on medication labels, such as keeping track of 
medication despite changes in brand or packaging and the value in having RFU on 
medications in emergency situations. Additionally, the patients interviewed described 
using RFU to support decision making regarding their medications, as opposed to 
serving as a reminder to take a medication.  
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5.4.1 Limitations 
While participants were varied in gender, age and understanding of their 
medications, they were all from a single geographic region in a publicly funded 
healthcare system. The findings may be different in other areas. Currently, patients in 
this region lack electronic access to their own healthcare records (ie, via a patient 
portal). These patients may thus lack an understanding of how these systems could 
benefit them, however the role that communicating RFU in could play benefiting them 
is universal. Additionally, patients volunteered to participate in this study, leading to a 
potentially biased sample who may have a stronger understanding of their medications 
than the general population.  
5.4.2 Conclusion 
This study demonstrated the value of RFU for patients and explores a number of 
ways it could be effectively communicated, with respect to both format and delivery 
method. These results can be used to advocate for patients to have access to RFU on 
their medication labels, to help patients make decisions about taking their medications, 
and could improve patient adherence with prescribed medications. By keeping in mind 
the diverse group of people who may ultimately need to learn a medications’ RFU from 
its label, prescribers and pharmacists should ensure that the RFU information included 
is understandable by a wide range of people.  
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Chapter 6: Conclusion and Future Work 
The analyses of the interviews presented indicate the value of adding RFU to 
prescriptions and medication labels to pharmacists, prescribers and patients. 
Additionally, improvements to interprofessional communication and patient 
counselling could be realized by ensuring pharmacists and patients are aware of 
medications’ RFU. This has the potential to ultimately improve interprofessional 
communication and patient safety.  
 Ensuring the addition of RFU as a matter of course on prescriptions and 
medication labels will require collaboration by a number of stakeholders before it 
becomes commonplace. This thesis demonstrates the value of continued engagement 
with prescribers to promote the addition of RFU on prescriptions to support 
pharmacist collaboration. This may take the form of engaging with regulatory bodies, 
interest groups or even individual prescribers for a more grassroots approach.(41) 
Research and practice still needs to happen to ultimately illustrate the benefits of 
adding RFU to prescribers by demonstrating tangible time saving, such as a decrease in 
callbacks. 
 Additional research needs to be conducted to determine the time saved by 
prescribers on callbacks if RFU is added, as well as improvements in patient 
understanding of their medications as well as patient adherence to prescribed 
treatment regimens. Further, research must be completed learn the perspectives of 
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people living with an STI, the human immunodeficiency virus (HIV) or acquired 
immune deficiency syndrome (AIDS), and/or mental health illnesses, to best determine 
how to communicate and label information with regards to those conditions. Ensuring 
that the inclusion of RFU is considerate of people no matter their circumstances is 
important to make sure patients feel respected, and is reflective of patient-centered 
care.  
 As Canada’s PrescribeIT® system continues to be rolled out, opportunities to 
promote the clear communication of information around prescriptions present 
themselves. These should include incorporating initiatives like Schiff’s indications-
based prescribing, improving medication labels to be more useful to patients, and 
requiring that RFU is included on prescriptions.(11,31) These charges will take time but 
can be aided by legislation put forward by individual provinces and territories, or 
federally, potentially as a component of a national pharmacare rollout. There are many 
changes happening in the areas of medication management, legislation, and health 
information technology, which should be seen as an opportunity to help Canadians stay 





Appendix A: Survey Faxed to Pharmacists 
Fax to return to: 519-883-7580  
Attention: Kelly Grindrod (University of Waterloo School of Pharmacy) 
SURVEY QUESTIONS FOR PHARMACISTS 
We are looking at how information about a patient’s reason for using a medication is 
shared between patients, pharmacists, and physicians. To answer the following 
questions, think about your own practice. 
Note: When we say “reason for use”, we are referring to the reason a medication was 
prescribed. This is also commonly called the “indication for treatment”. For example, for 
hydrochlorothiazide, the reason for use may be hypertension. 
 
#     PHARMACIST Questions 
1. How often do you see a reason for use included on a prescription sent to you by 
a prescriber? 
• Never  
• Rarely  
• Sometimes  
• Often  
• Always 
 
2.  Based on your experience, what proportion of physicians would be willing to 
share the “reason for use” with the pharmacist? 
• None  
• A Few  
• Half  
• Most  
• All 
 
3.  If the prescription included the “reason for use”, would you be willing to include 
it on the patient’s medication label? 
• Yes 
• No      
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4.  If the prescription included the “reason for use”, do you think pharmacists 
should record it into a region-wide drug record such as ClinicalConnect or the 
Ontario Drug Benefit Profile Viewer? 
• Yes   
• No 
 
5.  How beneficial would it be for you to have access to "reason to use" information 
directly from the physician? 
• Not at all 
• A little  
• Somewhat   
• Quite a bit    
• A great deal 
 
6.  How strongly do you agree/disagree that patients should have access to “reason 
for use” for their prescriptions? 
• Strongly Disagree    
• Disagree    
• Neutral    
• Agree    
• Strongly Agree 
 
Would you be willing to participate in a 1-hour interview? We will provide $150 in 
appreciation of your time at the end of the interview. Please indicate your choice below. 
• Yes, I would be interested in participating in a 1-hour interview to discuss 
this further. 
Name:       
Phone:      
Email:       
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Appendix B: Interview Questions for Pharmacists 
We are looking at how information about a patient’s reason for using a medication is 
shared between patients, pharmacists, and physicians. To answer the following 
questions, think about your own practice. 
Note: When we say “reason for use”, we are referring to the reason a medication was 
prescribed. This is also commonly called the “indication for treatment”. For example, for 
hydrochlorothiazide, the reason for use may be hypertension. 
1. What is your gender?  
• Man  
• Woman  
• Non-binary  
2. How many years of experience as a pharmacist do you have?   
3. What type of pharmacy do you work at? 
• Independent  
• Chain store 
• Family health team   
• Other: 
 
4. What is the computer system you use? 
 
5. Have you used other computer systems, besides which you currently use? 
• Yes  
• No 
o Which one(s)? 
o Which ones do you feel most comfortable with? 
o Why? 
We are going to talk about your experiences with the use of the system you currently use. 
1. How often do you see a “reason for use” included on a prescription sent to you 
by a prescriber? 
• Never  
• Rarely  
• Sometimes  
• Often  
• Always 
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2. Based on your experience, what proportion of physicians would be willing to 
share the “reason for use” with the pharmacist? 
• None  
• A Few  
• Half  
• Most  
• All 
 
3. Think back to the past week. Describe how you typically identified the reason 
medications were being prescribed? 
• Potential probes:  
o Do you ask the patient?  
o Do you verify your assumptions with the patient? 
 
4. How effective are pharmacists at determining the “reason for use” by reviewing 
the prescription (without asking the patient or physician)? 
• Not too much 
• A little  
• Somewhat    
• Quite a bit    
• Very much 
 
5. Some exploratory research found that pharmacists are incorrect about 1 in 10 
times when determining the “reason for use”. Does that surprise you?  
• Yes   
• No 
o If yes, why? 
o If no, why not? 
 
6. Describe what you do with “reason for use” information? 
 
7. Is the “reason for use” documented?    
• Yes 
• No 
• It depends (please explain) 
o Who is it shared with?  
 Patients    
 Physicians   
 Others (who are they?) 
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8. Who has access to the reason to use information? 
 
9. Do you ever place the “reason for use” on prescription labels for patients?  
• Yes    
• No  
• It depends 
o If yes, when do you decide to do this? 
 
10. Think back to the last month, when you were filling prescriptions for patients, 
how would they know the reason the drug was being prescribed? 
• What do you tell your patients about the reason you are dispensing a 
medication? 
 
11. If the prescription included the “reason for use”, would you be willing to include 
it on the patient’s medication label? 
• Yes 
• No 
• It depends (please explain) 
 
 
12. If the prescription included the “reason for use”, do you think pharmacists 
should record it into a region-wide drug record such as ClinicalConnect or the 




13. How beneficial would it be for you to have access to "reason to use" information 
directly from the physician?    
• Not at all    
• A little    
• Somewhat    
• Quite a bit    
• A great deal 
o If your answer was no, can you tell us why? 
o If your answer was yes, what are those foreseeable advantages? 
 
14. How strongly do you agree/disagree that patients should have access to “reason 
for use” for their prescriptions? 
• Strongly Disagree    
• Disagree    
• Neutral    
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• Agree    
• Strongly Agree 
15. Over the last week, describe how you monitored drug therapy in your patients? 
 
16. What does “monitor drug therapy” mean to you? 
 
17. Over the last week, describe how did you typically assess the safety of prescribed 
medications? Efficacy? Adherence? 
 
18. Describe your relationship with your patients. 
We are going to talk about would happen if the "reason to use" was added to the current 
system. 
1. Over the last week, can you describe a time when you could have used this 
information?   
• Yes   
• No 
 
2. If you had access to a reason for use, what level of detail would you need? 
• Just the reason for use 
• The reason for use and more background behind it 
o If you choose second choice, explain (e.g., lab test values or 
diagnostic reasoning?) 
 
3. What should the “reason for use” information that you get look like? (please 
explain) 
• In what section of the system should this information be presented?  
• How should it be shared? 
 
4. If a diagnostic code (e.g., ICD-9 codes) was added to the prescription, would that 
be good enough? 
• Yes    
• No  
• It depends 
o [If the pharmacist isn’t aware of what an ICD-9 code is, physicians 
often code a diagnosis in their computer system using a system 
such as ICD-9. The code is used to track information about the 
patient and to bill for their services. The ICD-9 code includes a 5-
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digit number and the name of the diagnosis such as 530.81 
Gastroesophageal reflux.] 
 
5. Would you prefer that the prescriber type the diagnosis onto the prescription 
rather than using a pre-set code? 
• Yes    
• No  
• It depends 
 
 
6. How detailed would you expect the typed “reason for use” to be? 
• A few words   
• One sentence   
• Couple sentences 
 
7. How variable would you expect a free form typed “reason for use” to be?  
• Not at all    
• A little    
• Somewhat    
• Quite a bit    
• A great deal 
 
 
8. Do you think prescribers would need help documenting the “reason for use” on 
prescriptions?  
• Yes    
• No  
 
9. If the “reason for use” is being communicated to the patient, what type of 
language should be used? 
• Lay terms  
• Medical terms 
 
10. When a medication is initially prescribed, who should be responsible for 
translating the “reason to use” information into lay language for the patient?  
• Pharmacist 
• Physicians  
• Both 
 
11. Who else should have access to reason for use information? 
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12. Do you have concerns about the sharing of reason for use information with 
pharmacists or others on the care team?  
• Yes    
• No  
• It depends 
 
13. Does the "reason for use" solve anything?  
• Yes    
• No  
o Why? 
o How would it change your practice? 
 
14. Do you have any final comments or concerns? 
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Appendix C: Interview Questions for Physicians and Nurse 
Practitioners 
1. What is your gender?  
• Man  
• Woman  
• Non-binary 
 
2. How many years have you been a physician or a nurse practitioner for?  __ 
 
3. Are you a family doctor?    
• Yes 
• No 
o If no, what is your medical specialty  
 
4. What type of practice do you have? 
• Independent 
• Family health organization 
• Family health team 
• Other 
 
5. What is the electronic medical record (EMR) system you use in your office?  
 
6. Have you used other EMR systems, besides which you currently use? 
• Yes  
• No 
o If you do, which one(s)?   
o With which one do you feel most comfortable?       
o Why? 
 
We are going to talk about your experiences in the use of the current system. 
 
1. How often do you enter reason to use information into the computer when you 
are writing your prescriptions? 
• Never  
• Rarely  
• Sometimes  
• Often  
• Always 
o If you do, who sees the reason for use information that you 
record? 
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2. When you were writing prescriptions, did you ever record the “reason for use” in 
your EMR? 
• If yes, how? 
• If no, why not? 
 
3. Did you ever include it on the prescription?  
• Yes    
• No  
• It depends 
 
4. Would you be willing to share reason for use with the pharmacist?  
• Yes    
• No  
 
5. Do pharmacists need to know the “reason for use” for a prescription?  
• Yes    
• No  
• It depends 
o If yes, how? 
o If no, why not? 
 
6. If the reason for use wasn’t given to a pharmacist, describe how you think a 
pharmacist identifies the “reason for use” of a medication? 
 
7. Describe what you think a pharmacist could do with “reason for use” 
information? 
 
8. Would you be willing to have the reason for use printed on the patient’s 
medication label? 
• Yes    
• No  
• It depends 
 
9. Would you be willing to have the reason for use shared on a region-wide drug 
record such as ClinicalConnect or the Ontario Drug Benefit Profile Viewer?  
• Yes    
• No  
• It depends 
o Why / why not? 
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10. If you knew other healthcare providers were going to see the reason for use for 
the medications you prescribe, would you write the “reason for use” in a 
different way than you would for your own records? 
• Yes 
• No 
o If yes, how would it be different? 
 
11. How beneficial would it be for you to share the "reason to use" with pharmacists 
and patients?  
• Not at all    
• A little    
• Somewhat    
• Quite a bit    
• A great deal 
o If your answer were no, can you tell us why?   
o If your answer was yes, what are those foreseeable advantages in 
each case (with other physicians, the pharmacist, and the patient)? 
 
12. How strongly do you agree/disagree that patients should have access to “reason 
for use” for their prescriptions? 
• Strongly Disagree    
• Disagree    
• Neutral    
• Agree    
• Strongly Agree 
 
 
13. Do you have any concerns about adding “reason for use” to prescriptions?  
• Yes    
• No  
• It depends (please explain) 
 
14. Think back to the last month, when you were writing prescriptions for patients, 
how would they know the reason the drug was being prescribed? What do you 
tell your patients about the reason you are prescribing a medication? 
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1. Imagine yourself in a situation where you are treating a new patient. You are 
looking at their medication list. How much information about the “reason for 
use” would you need to be able to renew their old medications? 
a. Diagnostic codes (e.g., ICD-9 codes)?  
• Yes  
• No    
• It depends 
b. Free form notes?  
• Short answer (less than a sentence)   
• Long answer (more than a sentence) 





2. What is the easiest way to share “reason for use” information with pharmacists 
and other physicians outside of your workplace? 
 
3. If the “reason for use” was added to the prescription, what type of language 
should be used? 
• Lay terms 
• Medical terms 
 
4. When a medication is initially prescribed, who should be responsible for 
translating the “reason to use” information into lay language for to the patient? 
• Physician    
• Pharmacist  
• Both 
 
5. How do you envision yourself including reason to use information on a 
prescription if it was mandatory? 
 
6. How would it affect your workflow? What would be good? What would you 
worry about? 
 
7. How would mandatory reason to use information influence your relationship 
with your patients? With other physicians? With pharmacists? 
 
8. Do you have any final thoughts? 
Would you suggest any colleagues who may be willing to speak with us? 
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Appendix D: Standards for Reporting Qualitative Research 
Checklist 
Note: this checklist was completed for the research in all of Chapters 3, 4 and 5. Only one 
completed checklist is included here.  
Standards for Reporting Qualitative Research (SRQR)*   
http://www.equator-network.org/reporting-guidelines/srqr/  
 
Title and abstract 
Page/line 
no(s). 
Title - Concise description of the nature and topic of the study Identifying 
the study as qualitative or indicating the approach (e.g., ethnography, 
grounded theory) or data collection methods (e.g., interview, focus group) 
is recommended Y  
Abstract  - Summary of key elements of the study using the abstract format 
of the intended publication; typically includes background, purpose, 





Problem formulation - Description and significance of the 
problem/phenomenon studied; review of relevant theory and empirical 
work; problem statement  Y 
Purpose or research question - Purpose of the study and specific objectives 





Qualitative approach and research paradigm - Qualitative approach (e.g., 
ethnography, grounded theory, case study, phenomenology, narrative 
research) and guiding theory if appropriate; identifying the research 
paradigm (e.g., postpositivist, constructivist/ interpretivist) is also 
recommended; rationale**  Y 
 
 




Researcher characteristics and reflexivity - Researchers’ characteristics 
that may influence the research, including personal attributes, 
qualifications/experience, relationship with participants, assumptions, 
and/or presuppositions; potential or actual interaction between 
researchers’ characteristics and the research questions, approach, 
methods, results, and/or transferability  Y 
Context - Setting/site and salient contextual factors; rationale**  Y 
Sampling strategy - How and why research participants, documents, or 
events were selected; criteria for deciding when no further sampling was 
necessary (e.g., sampling saturation); rationale**  Y 
Ethical issues pertaining to human subjects - Documentation of approval 
by an appropriate ethics review board and participant consent, or 
explanation for lack thereof; other confidentiality and data security issues  Y 
Data collection methods - Types of data collected; details of data collection 
procedures including (as appropriate) start and stop dates of data collection 
and analysis, iterative process, triangulation of sources/methods, and 
modification of procedures in response to evolving study findings; 
rationale**  Y 
Data collection instruments and technologies - Description of instruments 
(e.g., interview guides, questionnaires) and devices (e.g., audio recorders) 
used for data collection; if/how the instrument(s) changed over the course 
of the study  Y 
Units of study - Number and relevant characteristics of participants, 
documents, or events included in the study; level of participation (could be 
reported in results)  Y 
Data processing - Methods for processing data prior to and during analysis, 
including transcription, data entry, data management and security, 
verification of data integrity, data coding, and anonymization/de-
identification of excerpts  Y 
Data analysis - Process by which inferences, themes, etc., were identified 
and developed, including the researchers involved in data analysis; usually 
references a specific paradigm or approach; rationale**  Y 
Techniques to enhance trustworthiness - Techniques to enhance 
trustworthiness and credibility of data analysis (e.g., member checking, 








Synthesis and interpretation - Main findings (e.g., interpretations, 
inferences, and themes); might include development of a theory or model, 
or integration with prior research or theory  Y 
Links to empirical data - Evidence (e.g., quotes, field notes, text excerpts, 





Integration with prior work, implications, transferability, and 
contribution(s) to the field - Short summary of main findings; explanation 
of how findings and conclusions connect to, support, elaborate on, or 
challenge conclusions of earlier scholarship; discussion of scope of 
application/generalizability; identification of unique contribution(s) to 
scholarship in a discipline or field  Y 





Conflicts of interest - Potential sources of influence or perceived influence 
on study conduct and conclusions; how these were managed  Y 
Funding - Sources of funding and other support; role of funders in data 
collection, interpretation, and reporting  Y 
*The authors created the SRQR by searching the literature to identify guidelines, reporting standards, and 
critical appraisal criteria for qualitative research; reviewing the reference lists of retrieved sources; and 
contacting experts to gain feedback. The SRQR aims to improve the transparency of all aspects of qualitative 
research by providing clear standards for reporting qualitative research.      
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Appendix E Interview Questions for Patients 
Note: some questions were asked as a part of a Prescription Label Design Workshop by 
Hussein et al. 
 
First, we are going to ask you a few questions about yourself. 
Demographic questions: 
1. What is your age? 
 





Questions related to your medication history 
1. How many medications do you take regularly?  
2. In the last month, can you tell me what medications you took and why you took 
each of your medications? 
3. Do you keep any lists of these medications (in a file, on a computer, etc.)? 
 
4. Would you be comfortable with us taking a picture of these records? We will 
ensure that all identifying information is kept confidential and protected. 
 
We are going to talk about how you interact with the current system. In particular we are 
interested in something called “reason for use”. This is the reason a medication was 
prescribed to you. For example, the reason for use with Tylenol may be “a headache” our 
“arthritis pain”. 
Questions related to how you function in the current system: 
1. How do you currently find out what your medications are for? 
 
2. Where do you place this information? (Potential probes: Do you write it down? 
Do you keep it put in your phone? Do you make medication lists?) 
 
3.  In the past, has the reason for use information been shared with you? 
a. Who shared this type of info with you? Pharmacist? Physician? 
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b. When did they share it?  Did you have to ask to find out or was this info 
provided? 
c. Please provide an example of what type of language was used to explain a 
medication. How useful was this? 
d. Was there a time that the reason for using a medication a professional 
provided was not clear or useful?  Please explain.  
e. Can you recall a time that learning the reason for using a medication was 
particularly helpful for you?  Please tell me more.  
 
4. Who else is aware of the reasons you are taking your medications? 
 
5. Can you recall a time when you did not know the reason for a medication? What 
implications did this have?  
a. What did you do to find out (if appropriate to ask)? (ask user to draw out 
the steps they took to find out the reason for use information) 
 
6. On a scale of 1 to 5, with 5 being “very important,” how important is it for you to 
know what your medication are for? Please tell us more. 
 
We are going to talk about what would happen if the "reason to use" was added to the 
computer systems that doctors, pharmacists, and nurses use to help you manage your 
medications. 
Questions related to being provided with “reason to use” information: 
1. How would you feel if the reason for use was shared with your pharmacist on 
every prescription, including refills? 
 
2. How should the reason for use information be presented to you? (Probing 
questions: Would you like it to be on your prescriptions? Receipts? Medication 
lists? In an app or website that you use to view or access your prescriptions?) 
 
3. How would the reason for use information affect your ability to make decisions 
about your medications? 
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4. Who else should have access to your reason for use information? This can be 
anyone in your life such as healthcare professionals, care providers, or family 
members. Why? 
 
Prescription Label Design Workshop 
 
Now we are going to design a prescription label that would hypothetically incorporate the 
“reason to use” information. (Hand participant example prescription label template) 
 




1. Why did you choose this location? 
 
2. How much detail would you expect? (Potential probes: Short-hand? Long-hand?) 
 
3. If you could rearrange the information on this prescription label, would you? 
a. If yes, please show us. (Hand participant blank prescription label template, 
corresponding prescription label information, and tape) 
b. Why did you choose the layout you did?    
 
4. Do you have any concerns regarding the sharing of reason for use information 
with the pharmacist or on your prescription labels? If so, what? 
 
5. On what occasion(s) would you like this information on your prescription label? 
 
6. On what occasion(s) would you not like this information on your prescription 
label?  
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7. Do you prefer the phrase ‘reason to use’ or ‘reason for use’? 
 
8. Who do you think would benefit from this new design? 
 
9. How will you use this new design? 
 
10. Does this adding reason to prescription labels solve the problem we’re trying to 
solve? 
 
11. How might we think about this design differently? 
 
12. Is there any other way to accomplish this design problem? 
 
13. What do you believe is the end result of doing this? 
 
14. Do you have any final thoughts, comments, or concerns? 
 
15.  On a scale of one to 5, how much do you depend on your prescription label for 
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